Compositions and methods for treating chronic HBV infection
Selective inhibitors of senescence-associated BCL-2 family proteins effectively target and clear HBV cccDNA from infected cells, addressing the limitations of current therapies by significantly reducing viral load and senescent cells, offering a potential cure for chronic HBV infection.
Patent Information
- Application Number
- PCT/AU2026/050475
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-13
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
Current antiviral therapies for chronic hepatitis B virus (HBV) infection only suppress viral replication but do not cure the infection, leading to a high risk of liver cancer and cirrhosis, and existing treatments fail to eliminate the viral covalently closed circular DNA (cccDNA) template, which is essential for virus replication.
Administering selective inhibitors of senescence-associated BCL-2 family proteins to target and clear cccDNA from virus-infected cells, thereby reducing the number and amount of HBV cccDNA and senescent cells.
The treatment significantly decreases HBV cccDNA levels by at least 2-fold to 4-fold and reduces senescent infected cells by over 50%, potentially curing the chronic infection and preventing its progression to liver cancer.
Smart Images

Figure IMGF000018_0001 
Figure IMGF000031_0001 
Figure IMGF000044_0001_TABLE
Abstract
Description
[0001] “COMPOSITIONS AND METHODS FOR TREATING CHRONIC HBV INFECTION”
[0002] RELATED APPLICATIONS
[0003] This application claims priority from Australian provisional patent application no.
[0004] 2025901837 entitled “Compositions and methods for treating chronic HBV infection” filed on 13 May 2025, the entire contents of which are hereby incorporated by reference.
[0005] TECHNICAL FIELD
[0006] The present disclosure relates generally to compositions for treatment, monitoring and diagnosis of hepatitis B virus (HBV) infection in a subject, specifically, chronic and / or latent infection, and methods, uses, and kits pertaining to the composition and methods.
[0007] BACKGROUND
[0008] Chronic hepatitis B is an incurable disease that affects -300 million people worldwide with significant economic impact: the Australian health costs in 2017 were $308M. Infection with the Hepatitis B Virus (HBV) also results in -1.1M global deaths each year. HBV disproportionately affects vulnerable and underserved populations, including migrants, people from poorer socio-economic backgrounds, and First Nations Australians. In Australia, HBV-related deaths have only decreased by <3% relative to 2017 levels. This level is incompatible with WHO elimination targets of 65% reduction by 2030. Without curative treatments, the WHO predicts that chronic HBV infections and its impacts will persist past 2080. People with chronic HBV have a 25% lifetime risk of dying from liver cancer or cirrhosis. In fact, persons with chronic HBV infection i.e., carriers, have at least 12 times higher risk of developing hepatocellular carcinoma than non-carriers, and HBV causes 60-80% of the world's primary liver cancers. As a consequence, HBV ranks second only to tobacco as a known human carcinogen, and HBV infection has been reported to increase liver cancer risk by the same rate as daily smoking a packet of cigarettes raises lung cancer risk. HBV, and hepadnaviruses more broadly, therefore represent a significant global health burden.
[0009] Although vaccines against HBV are available, the rate of HBV infection in the population remains high. Furthermore, the majority of existing antiviral therapies for chronic HBV infection have only limited inhibitory effects on viral gene expression and replication in the majority of chronically infected patients. However, even for those treatments that do stop viral replication in liver cells, they do not cure the infection, leaving patients at risk of developing liver cancer. It is unclear how HBV persists in theliver, but despite the combination of long-term antiviral therapy and substantial liver cell turnover, HBV-infected cells persist.
[0010] For these reasons, there remains a need for new therapeutic approaches to treat HBV infection, as well as approaches for preventing the prevalence of chronic HBV infection within the population.
[0011] Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each of the appended claims.
[0012] SUMMARY
[0013] The present disclosure is based, inter alia, on the surprising finding by the inventors that inhibitors of senescence-associated proteins clear cccDNA from virus infected cells. Specifically, the inventors have shown for the first time that a subset of cells which resist mitosis harbour cccDNA, and that these cells can be targeted to treat chronic infection.
[0014] Accordingly, in some embodiments, the present disclosure provides a method of treating a Hepadnavirus infection in a subject suffering therefrom, comprising administering to the subject a selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0015] In some embodiments, provided herein is a use of a selective inhibitor of one or more senescence-associated BCL-2 family proteins in the preparation of a medicament for treatment of Hepadnavirus infection in a subject suffering therefrom.
[0016] In some embodiments, provided herein is a pharmaceutical composition for treating Hepadnavirus infection in a subject suffering therefrom, said pharmaceutical composition comprising a selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0017] In some examples, the Hepadnavirus is Hepatitis B virus (HBV).
[0018] In some examples, the subject is suffering from chronic HBV infection.
[0019] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject decreases expression of HBV cccDNA in the subject.
[0020] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject decreases the number of HBV cccDNA molecules in the subject.In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject decreases the amount of HBV cccDNA in the subject.
[0021] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject decreases the number of HBV cccDNA molecules in the subject by at least 2-fold relative to the level of HBV cccDNA in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0022] In some examples, HBV cccDNA is decreased in the subject by at least 2-fold relative to the level of HBV cccDNA prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject. In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject decreases the number of HBV cccDNA molecules in the subject by at least 3 -fold relative to the level of HBV cccDNA in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0023] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject decreases the amount of HBV cccDNA in the subject by at least 3 -fold relative to the level of HBV cccDNA in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0024] In some examples, HBV cccDNA is decreased by at least 3 -fold in the subject relative to the level of HBV cccDNA in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0025] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject decreases the number of HBV cccDNA molecules in the subject by at least 4-fold relative to the level of HBV cccDNA in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0026] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject decreases the amount of HBV cccDNA in the subject by at least 4-fold relative to the level of HBV cccDNA in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.In some examples, HBV cccDNA is decreased by at least 4-fold in the subject relative to the level of HBV cccDNA in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject.
[0027] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject reduces the number of senescent cells infected by HBV in the subject relative to the number of senescent cells infected by HBV in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0028] In some examples, the number of senescent cells infected by HBV in the subject is reduced by more than 50%.
[0029] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject reduces the number of cells infected by HBV in the subject by more than 50%. For example, the cells are senescent cells.
[0030] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins results in clearance of senescent cells infected by HBV in the subject.
[0031] In some examples, the selective inhibitor of one or more senescence-associated BCL-2 family proteins is administered orally to the subject.
[0032] In some examples, the medicament is an oral formulation.
[0033] In some examples, the pharmaceutical composition is an oral formulation.
[0034] In some examples, the selective inhibitor of one or more senescence-associated BCL-2 family proteins is administered to the subject in combination with one or more additional treatments or treatment regimes.
[0035] In some examples, the subject is receiving one or more additional treatments or treatment regimens for HBV infection.
[0036] In some examples, the additional treatment comprises antiviral therapy and / or interferon. For example, the additional treatment comprises antiviral therapy. For example, the additional treatment comprises interferon. For example, the additional treatment comprises antiviral therapy or interferon. For example, the additional treatment comprises antiviral therapy and interferon.
[0037] In some examples, the additional treatment comprises a direct-acting antiviral (DAA) and / or immune modulator.
[0038] In some examples, the antiviral therapy comprises a nucleoside analogue.
[0039] In some examples, the antiviral therapy comprises a nucleotide analogue.In some examples, the antiviral therapy comprises a nucleotide analogue and a nucleoside analogue.
[0040] In some examples, the antiviral therapy comprises one or more of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir), and adefovir (Hepsera).
[0041] In some embodiments, provided herein is method of preventing chronic Hepadnavirus infection in a subject suffering from acute hepadnavirus infection, comprising administering to the subject a selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0042] In some examples, provided herein is a method of preventing chronic HBV infection in a subject suffering from acute hepadnavirus infection, comprising administering to the subject a selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0043] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins decreases expression of HBV cccDNA in the subject.
[0044] In some examples, HBV cccDNA is decreased in the subject by at least 2-fold relative to the level of HBV cccDNA prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0045] In some examples, HBV cccDNA is decreased by at least 3 -fold in the subject relative to the level of HBV cccDNA in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0046] In some examples, HBV cccDNA is decreased by at least 4-fold in the subject relative to the level of HBV cccDNA in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0047] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins reduces the number of senescent cells infected by HBV in the subject relative to the number of senescent cells infected by HBV in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0048] In some examples, the number of senescent cells infected by HBV in the subject is reduced by more than 50%.
[0049] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins results in clearance of senescent cells infected by HBV in the subject.In some examples, the selective inhibitor of one or more senescence-associated BCL-2 family proteins is administered orally.
[0050] In some examples, the selective inhibitor of one or more senescence-associated BCL-2 family proteins is administered in combination with one or more additional treatments or treatment regimes.
[0051] In some examples, the additional treatment comprises antiviral therapy and / or interferon.
[0052] In some examples, the additional treatment comprises a direct-acting antiviral (DAA) and / or immune modulator.
[0053] In some examples, the antiviral therapy comprises a nucleoside analogue.
[0054] In some examples, the antiviral therapy comprises one or more of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir), and adefovir (Hepsera).
[0055] In some embodiments, provided herein is a use of a selective inhibitor of one or more senescence-associated BCL-2 family proteins in the preparation of a medicament for treatment of Hepadnavirus infection in a subject suffering therefrom.
[0056] In some examples, the subject is suffering from chronic HBV infection.
[0057] In some examples, the medicament is for use combination with one or more additional treatments or treatment regimes.
[0058] In some examples, the additional treatment comprises antiviral therapy and / or interferon.
[0059] In some examples, the antiviral therapy comprises a nucleoside analogue.
[0060] In some examples, the antiviral therapy comprises one or more of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir), and adefovir (Hepsera).
[0061] In some embodiments, provided herein is a use of a selective inhibitor of one or more senescence-associated BCL-2 family proteins in the preparation of a medicament for preventing chronic Hepatitis B virus (HBV) infection in a subject suffering from acute HBV infection.
[0062] In some examples, the medicament is for use combination with one or more additional treatments or treatment regimes.
[0063] In some examples, the additional treatment comprises antiviral therapy and / or interferon.
[0064] In some examples, the antiviral therapy comprises a nucleoside analogue.In some examples, the antiviral therapy comprises one or more of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir), and adefovir (Hepsera).
[0065] In some embodiments, provided herein is a pharmaceutical composition comprising a selective inhibitor of one or more senescence-associated BCL-2 family proteins for treating Hepadnavirus infection in a subject suffering therefrom.
[0066] In some examples, the composition is for treating chronic HBV infection.
[0067] In some examples, the selective inhibitor of the senescence-associated BCL-2 family protein is a selective inhibitor of BCL-2 / BCL-XL, a selective inhibitor of BCL-2 / BCL-XL / BCL-W, or a selective inhibitor of BCL-XL.
[0068] In some examples, the composition is for use combination with one or more additional treatments or treatment regimes.
[0069] In some examples, the additional treatment comprises antiviral therapy and / or interferon.
[0070] In some examples, the antiviral therapy comprises a nucleoside analogue.
[0071] In some examples, the antiviral therapy comprises one or more of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir), and adefovir (Hepsera).
[0072] A pharmaceutical composition comprising a selective inhibitor of one or more senescence-associated BCL-2 family proteins for preventing chronic Hepatitis B virus (HBV) infection in a subject suffering from acute HBV infection.
[0073] In some examples, the composition is for use combination with one or more additional treatments or treatment regimes.
[0074] In some examples, the additional treatment comprises antiviral therapy and / or interferon.
[0075] In some examples, the antiviral therapy comprises a nucleoside analogue.
[0076] In some examples, the antiviral therapy comprises one or more of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir), and adefovir (Hepsera). For example, the antiviral therapy comprises entecavir (Baraclude). For example, the antiviral therapy comprises tenofovir disaproxil fulmarate (Viread). For example, the antiviral therapy comprises tenofovir alafenamide (Vemlidy). For example, the antiviral therapy comprises lamivudine (Epivir). For example, the antiviral therapy comprises adefovir (Hepsera).
[0077] In some embodiments, provided herein is a method of monitoring disease progression in a subject with Hepadnavirus infection, the method comprising: i) detecting the presence of one or more markers of cell senescence and determining a level ofsenescent Hepadnavirus infected cells in a sample taken from a subject; and ii) comparing that level to a pre-determined level; wherein a higher level in the subject sample is indicative of disease progression, and a lower level in the subject sample is indicative of disease regression.
[0078] In some embodiments, provided herein is a method of monitoring progression of hepadnavirus infection in a subject currently or previously infected with hepadnavirus, the method comprising: i) determining a level of senescent hepadnavirus infected cells in a sample obtained from the subject based on the presence and / or level of one or more markers of cell senescence in the sample; ii) comparing the level of senescent hepadnavirus infected cells in the sample determined at i) to a reference level for senescent hepadnavirus infected cells; and iii) making a determination on progression of the hepadnavirus infection in the subject based on ii), wherein a level of senescent hepadnavirus infected cells in the sample which is higher than the reference level is indicative of worsening hepadnavirus infection and / or chronic hepadnavirus infection in the subject, wherein a level of senescent hepadnavirus infected cells in the sample which is lower than or equal to the reference level is indicative of regression or improvement in the hepadnavirus infection in the subject.
[0079] In some examples, the reference level is a pre-determined level. For example, a reference level is a level taken from the subject at an earlier time point. For example, a reference level is a level taken from a population sample. For example, a reference level is a level taken from a second subject with regressed infection. For example, a reference level is a level taken from a population of subjects with regressed infection.
[0080] In some examples, the hepadnavirus is HBV.
[0081] In some examples, the infection is a chronic infection.
[0082] In some examples, the sample is taken from a subject suffering from, or previously diagnosed with, chronic infection.
[0083] In some examples, a worsening hepadnavirus infection and / or chronic hepadnavirus infection is indicative that the subject is not responding to treatment for the infection, and a regression or improvement in the hepadnavirus infection is indicative that the subject is responding to treatment for the infection.
[0084] In some embodiments, provided herein is a method of prognosing or determining a likelihood that a subject with chronic hepadnavirus infection will respond well to a treatment regime, the method comprising: i) detecting the presence of one or more markers of cell senescence and determining a level of senescent hepadnavirus infected cells in a sample taken from a subject; and ii) comparing that level to a pre-determined level; wherein a higher level in the subject sample is indicative of reduced treatmentefficacy, and a lower level in the subject sample is indicative of increased treatment efficacy.
[0085] In some examples, the hepadnavirus is HBV.
[0086] In some examples, the infection is a chronic infection.
[0087] In some embodiments, provided herein is a method of screening a subject with HBV for a clinical trial, wherein a subject is included in the clinical trial if the presence of one or more markers of cell senescence is detected in a sample taken from the subject.
[0088] In some examples, the clinical trial is a trial for treatment of HBV.
[0089] In any embodiment provided herein, in some examples, the senescence-associated BCL-2 family proteins are selected from the group consisting of BCL-2, BCL-XL, BCL-W, MCL-1, BFL-1 / A1, and BCL2L10 or their relevant orthologues, or senescence-associated isoforms of any one thereof.
[0090] In any embodiment provided herein, in some examples, the selective inhibitor of the senescence-associated BCL-2 family protein is a selective inhibitor of BCL-2 / BCL-XL, a selective inhibitor of BCL-2 / BCL-XL / BCL-W, or a selective inhibitor of BCL-XL.
[0091] In any embodiment provided herein, in some examples, the selective inhibitor of the senescence-associated BCL-2 family protein is selected from a small molecule inhibitor, an oligonucleotide inhibitor, a polynucleotide inhibitor, a peptide inhibitor and a protein inhibitor.
[0092] In any embodiment provided herein, in some examples, the selective inhibitor of the senescence-associated BCL-2 family protein is a small molecule.
[0093] In any embodiment provided herein, in some examples, the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is selected from the group consisting of Navitoclax (ABT-263), A-1551852, A-1331852, A-1155463, A-1155463 dihydrochloride, A-1210477, Venetoclax (ABT-199), ABT-737, Sonrotoclax (BGB-11417), S63845, S64315 (MIK665), S55746 (BCL201), AZD5991, AZD4320, BT-1197, AMG-176, WEHI-539, IS21, Obatoclax Mesylate (GX15-070), Subatoclax (BL97C1), Maritoclax (Marinopyrrole A), TW-37, UML77, BDA-366, BM-1252, BXI-61, BXI-72, HA14-1, BDA366, APG-2575 (lisaftoclax), BH3I-1, DT2216, VU661013, a perylene quinone mycotoxin (e.g., Altertoxin I, Altertoxin II, and alterperylenol from Alternaria altemata) and derivatives thereof, gossypol and enantiomers thereof, AT-101, siRNA, Oblimersen, and tetrocarcin A secreted by Micromonospora sp.
[0094] In any embodiment provided herein, in some examples, the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is a small molecule BH3mimetic drug, preferably selected from Navitoclax (ABT-263) and Venetoclax (ABT-199).
[0095] In any embodiment provided herein, in some examples, the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is a small molecule drug DT2216.
[0096] In any embodiment provided herein, in some examples, the small molecule BH3 mimetic drug is Navitoclax (ABT-263).
[0097] In any embodiment provided herein, in some examples, the small molecule BH3 mimetic drug is Venetoclax (ABT-199).
[0098] In any embodiment provided herein, in some examples, the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is A-1551852.
[0099] In any embodiment provided herein, in some examples, the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is DT2216.
[0100] In any embodiment provided herein, in some examples, the method comprises administering to the subject Navitoclax.
[0101] In any embodiment provided herein, in some examples, the method comprises administering to the subject A-1551852.
[0102] In any embodiment provided herein, in some examples, the method comprises administering to the subject DT2216.
[0103] In any embodiment provided herein, in some examples, the method comprises administering to the subject both of Navitoclax and A-1551852.
[0104] In any embodiment provided herein, in some examples, the method comprises administering to the subject both of DT2216 and Navitoclax.
[0105] In any embodiment provided herein, in some examples, the method comprises administering to the subject both of DT2216 and A-1551852,
[0106] In any embodiment provided herein, in some examples, the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is A-l 155463.
[0107] In any embodiment provided herein, in some examples, the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is A-l 155463 dihydrochloride.
[0108] In any embodiment provided herein, in some examples, the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is WEHI-539.
[0109] In any embodiment provided herein, in some examples, the method comprises administering to the subject one or more of Navitoclax, A-1551852, WEHI-539, A-1155463, DT2216 and A-l 155463 dihydrochloride.In any embodiment provided herein, in some examples, the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is an oligonucleotide or polynucleotide.
[0110] In any embodiment provided herein, in some examples, the oligonucleotide inhibitor is an RNA interference (RNAi) molecule.
[0111] In any embodiment provided herein, in some examples, the polynucleotide inhibitor is an RNA interference (RNAi) molecule.
[0112] In some embodiments, the RNAi molecule is a selective inhibitor of the one or more senescence-associated BCL-2 family proteins.
[0113] In any embodiment provided herein, in some examples, the RNAi molecule is Oblimersen (G3139).
[0114] In any embodiment provided herein, in some examples, the subject is an animal. In any embodiment provided herein, in some examples, the subject is a bird or mammal.
[0115] In any embodiment provided herein, in some examples, the subject is a human.
[0116] BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1. Targeting persistent infected cells is key to preventing reinfection, eliminating all cccDNA, and curing chronic HBV.
[0117] FIG. 2. (A) Mitosis was induced in HBV-infected cells in vitro by serially passaging the culture. With limited mitosis (first 4 passages), cccDNA decreased consistent with models where cccDNA is lost after mitosis (dashes) rather than surviving in daughter cells (dashes and dots). After greater mitosis, a rare cell subset that maintains cccDNA was observable. (B) HBV-positive reservoir cells (triangles) express senescence markers P-galactosidase activity (P-gal) and p21 (not shown). Most infected cells prior to mitosis (arrows) do not express these markers. (C) Cells maintaining cccDNA were isolated by flow-sorting based on red fluorescence protein (RFP, expressed by the recombinant HBV system) and were subsequently analysed by RNAseq.
[0118] FIG. 3. Senolytic-induced reduction of senescent infected cells was observed in vitro by measuring secreted viral products (A) luciferase secretion from recombinant HBV and (B) direct quantification of cccDNA. (C) Senolytics in mice transduced with AAV constructs expressing GFP and given carbon tetrachloride to induce liver turnover was tested. In this model, treatment with Navitoclax led to 4-fold reduction in GFP-expressing liver cells.FIG. 4. Results demonstrating the specificity and sensitivity of pan-genotypic cinqPCR.
[0119] FIG. 5. Nanoluc Reporter virus assay A) Supernatant from HBV-nanoluc infected HepG2 NTCP taken every 3 days to monitor stability of Nanoluc. Serial passage of cells were done concurrently. Levels normalised to supernatant of unpassaged at day 14 post infection. Nanoluc expression declines over time, linear expression of nanoluc remains higher than expected relative to mathematical model of cccDNA loss in mitosis. B) Treatment of these cells at 1 day prior to 1:32 dilution results in reduction of luminescence in Navitoclax and A-1331852 treated conditions, ns non-significant ** p<0.01.
[0120] FIG. 6. HBV loss after each 1:2 passage was observed in vitro by direct quantification of cccDNA, consistent with the “loss” model until passage 5. Treatment with senolytics for 3 days at 1 day prior to passage 4 induced reduction of infected cells for Navitoclax, A-1551852, WEHI-539, A-l 155463, and A-l 155463 dihydrochloride and compared to DMSO controls.
[0121] FIG 7. Treatment using DT2216 at different doses was performed according to the schematic experimental timeline. (A) Treatment of passaged (5x 1 :2) HBV-infected cells with 500nM DT2216 for 4 days induced by direct quantification of cccDNA via cinqPCR. (B) Cell viability at various concentrations of DT2216 was measured a CCK8 assay (n = 3). Three trials were performed, using various doses of DT2216, as indicated. Each trial shows HBV cccDNA loss for DT2216 treated cells compared to control (DMSO).
[0122] DETAILED DESCRIPTION
[0123] General Definitions
[0124] Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g. in immunology, molecular biology, immunohistochemistry, biochemistry, genomics and pharmacology).
[0125] The present disclosure is performed without undue experimentation using, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA technology and immunology. Such procedures are described, for example in Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual,Cold Spring Harbor Laboratories, New York, Fourth Edition (2012), whole of Vols I, II, and III; DNA Cloning: A Practical Approach, Vols. I and II (D. N. Glover, Second Edition., 1995), IRL Press, Oxford, whole of text; Oligonucleotide Synthesis: APractical Approach (M. J. Gait, ed, 1984) IRL Press, Oxford, whole of text, and particularly the papers therein by Gait, ppl-22; Atkinson et al, pp35-81; Sproat et al, pp 83-115; and Wu et al, pp 135-151; 4. Nucleic Acid Hybridization: A Practical Approach (B. D. Hames & S. J. Higgins, eds., 1985) IRL Press, Oxford, whole of text; Immobilized Cells and Enzymes: A Practical Approach (1986) IRL Press, Oxford, whole of text; Perbal, B., A Practical Guide to Molecular Cloning (1984) and Methods In Enzymology (S. Colowick andN. Kaplan, eds., Academic Press, Inc.), whole of series.
[0126] As used herein, the singular forms of “a”, “and” and “the” include plural forms of these words, unless the context clearly dictates otherwise. For example, a reference to “a bacterium” includes a plurality of such bacteria, and a reference to “an antigen” is a reference to one or more antigens.
[0127] The term “and / or”, e.g., “X and / or Y” shall be understood to mean either “X and Y” or “X or Y” and shall be taken to provide explicit support for both meanings or for either
[0128] meaning.
[0129] Throughout this specification, the word “comprise” or variations such as “comprises” or “comprising” will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
[0130] The term “about” is used herein to mean approximately. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the recited numerical values. In general, the term “about” is used herein to modify a numerical value above and below the stated value by ± 0.1%, 0.5%, 1.0%, 5.0% or 10%. The extent of such tolerances and variances are well understood by persons skilled in the art. Typically, such tolerances and variances do not compromise the structure, function and / or implementation of the compositions and methods described herein.
[0131] As used herein, the term “subject” shall be taken to mean any individual, any animal including humans, for example a mammal, for example a bird. Exemplary subjects include but are not limited to humans and non -human primates, non-human mammals, and birds, for example ducks, snow geese, white storks, grey herons, cranes, and parrots. For example, the subject is a human, which can be an infant, a child, an adult or an elderly adult. For example, the subject is a non-human mammal. For example, thesubject is any animal that can develop a viral infection, wherein the virus is a cccDNA virus. For example, the subject is any animal that can develop a hepadnavirus infection. For example, the subject is any animal that can develop a hepatitis infection. For example, a subject is currently undergoing treatment for a viral infection, for example hepatitis. For example, a subject is not currently undergoing treatment for a viral infection, for example hepatitis. For example, the subject has been previously diagnosed with a cccDNA viral infection, for example a hepadnavirus infection, for example hepatitis. For example, the subject has not been previously diagnosed with a cccDNA viral infection, for example a hepadnavirus infection, for example hepatitis.
[0132] As used herein, the term “biological sample” refers to any material taken from the body of a subject that may carry the target compound or compounds of the tests described herein. In some examples, the biological sample is a tissue or cell thereof. For example, the sample is resected tissue, for example, a biopsy, for example, the sample is a cell or population of cells derived from a patient biopsy. For example, the sample is cells in culture, for example, any suitable cell line in vitro. For example, the sample is a reference sample. In one example, the biological sample is selected from a group consisting of whole blood, serum, plasma, urine, saliva, sweat, spinal fluid, sputum, cell lysate, cell culture medium and mixtures thereof. For example, the biological sample may be whole blood or fraction thereof (e.g., serum or plasma). For example, the biological sample is saliva. For example, the biological sample is biopsy tissue, for example minimally invasive biopsy tissue, for example, fine-needle biopsy. For example, the biological sample comprises between 1000-10000 cells. For example, the biological sample is less than 1000 cells. For example, the biological sample is less than 20 cells.
[0133] As used herein, the terms “treating”, “treat” or “treatment” include administering a selective inhibitor of one or more senescence-associated proteins or composition described herein to thereby reduce or eliminate at least one symptom of a specified disease or condition. For example, the disease or condition is chronic hepadnavirus infection, for example, chronic HB V infection.
[0134] As used herein, the term “preventing”, “prevent” or “prevention” includes providing prophylaxis with respect to occurrence or recurrence of a specified disease or condition in an individual. For example, the disease or condition is chronic hepadnavirus infection, for example, chronic HBV infection.
[0135] As used herein, the phrase “delaying progression of’ includes reducing or slowing down the progression of the disease or condition in an individual and / or at least one symptom of a disease or condition. For example, the disease or condition is chronic hepadnavirus infection, for example, chronic HBV infection.An “effective amount” refers to at least an amount effective, at dosages and for periods of time necessary, to achieve the desired result. For example, the desired result may be a therapeutic or prophylactic result. An effective amount can be provided in one or more administrations. In some examples of the present disclosure, the term “effective amount” is meant an amount necessary to effect treatment of a disease or condition, for example chronic hepadnavirus infection, for example, chronic HBV infection. In some examples of the present disclosure, the term “effective amount” is meant an amount necessary to effect a change associated with a disease or condition, for example chronic hepadnavirus infection, for example, chronic HBV infection. For example, an effective amount is an amount which reduces or clears senescent cells, for example, senescent cells harbouring cccDNA. The effective amount may vary according to the disease or condition to be treated, or the surrounding circumstances, such as any co-treatments, comorbidities, etc, and also according to the weight, age, racial background, sex, health and / or physical condition and other factors relevant to the individual being treated. Typically, the effective amount will fall within a relatively broad range (e.g. a “dosage” range) that can be determined through routine trial and experimentation by a medical practitioner. Accordingly, this term is not to be construed to limit the disclosure to a specific quantity or amount of the selective inhibitor of one or more senescence-associated proteins. The effective amount can be administered in a single dose or in a dose repeated once or several times over a treatment period. The repeated dose need can vary, i.e. the dose administered over a period of time may not be the same dose.
[0136] Those skilled in the art will appreciate that the present disclosure is susceptible to variations and modifications other than those specifically described. It is to be understood that the disclosure includes all such variations and modifications. The disclosure also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features. Thus, each feature of any particular aspect or embodiment of the present disclosure may be applied mutatis mutandis to any other aspect or embodiment of the present disclosure.
[0137] The present disclosure is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. Functionally equivalent products, compositions and methods are clearly within the scope of the disclosure, as described herein.
[0138] Throughout this specification, unless specifically stated otherwise or the context requires otherwise, reference to a single step, composition of matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e. oneor more) of those steps, compositions of matter, groups of steps or group of compositions of matter.
[0139] Hepatitis B Virus (HBV)
[0140] Hepatitus B virus (HBV) belongs to the family Hepadnaviridae. Hepadnaviruses have small, enveloped, spherical virions (virus particles) that are about 40-48 nm in diameter. The capsid contains a circular, partially double-stranded DNA molecule with a single-stranded DNA region and a DNA-dependent DNA polymerase. The DNA polymerase serves to fill the gap in the double-stranded DNA at the single stranded region. The activity of the polymerase is essential for the virus’s replication. Hepadnaviruses are further distinguished by the use of reverse transcriptase to synthesise a DNA copy of their genomic and pre-genomic RNA (pgRNA), respectively, for replication during the viral life cycle, and by an abundance of the soluble protein HBsAg (hepatitis B surface antigen).
[0141] The name hepadnavirus is an acronym for hepatitis DNA viruses. The prototype virus of the family Hepadnaviridae is hepatitis B virus, an important human pathogen that is the cause of both acute and chronic hepatitis and an increased risk of hepatic fibrosis and carcinoma. The family is divided into two genera: Orthohepadnavirus includes the mammalian viruses; Avihepadnavirus comprises the avian members. Mammalian, but not necessarily avian, hepadnaviruses are associated strongly with naturally occurring hepatocellular carcinomas in their natural hosts.
[0142] In some embodiments, a subject suffering from a Hepadnavirus infection is a mammal. In some embodiments, a subject suffering from a Hepadnavirus infection is a primate. In some embodiments, a subject suffering from a Hepadnavirus infection is a rodent. In some embodiments, a subject suffering from a Hepadnavirus infection is a bat (chiropteran). In some embodiments, a subject suffering from a Hepadnavirus infection is a carnivore. In some embodiments, a subject suffering from a Hepadnavirus infection is a cat. In some embodiments, a subject suffering from a Hepadnavirus infection is a dog. In some embodiments, a subject suffering from a Hepadnavirus infection is a perissodactyl. In some embodiments, a subject suffering from a Hepadnavirus infection is a horse. In some embodiments, a subject suffering from a Hepadnavirus infection is a eulipotyphla. In some embodiments, a subject suffering from a Hepadnavirus infection is a shrew-like mammal.
[0143] Hepatitis B virus causes the hepatitis B infection which affects the liver. Hepatitis B is transmitted parenterally or postnatally from infected mothers. It can also be transmitted by inoculation through broken or penetrated skin, or by mucosal contact withblood or other body fluids (mainly vaginal fluids and semen) from an infectious host, including a person.
[0144] HBV can cause a chronic infection and puts people at high risk of death from cirrhosis and liver cancer. The single greatest contributor to liver cancer is chronic infection with the hepatitis B virus (HBV), which is incurable and affects >300 million people. Current therapies only suppress virus replication and need to be taken lifelong. Even with treatment, the liver disease progression risk remains elevated. HBV-related disease is dependent on viral covalently closed circular DNA (cccDNA), the template for virus replication. Thus, elimination of cccDNA is the only pathway for a complete cure.
[0145] Acute infection during adulthood is self-limiting and results in flu-like symptoms that can progress to hepatocellular involvement as observed with the development of jaundice. The clinical symptoms generally last for a few weeks before resolving. After this acute phase, life-time immunity is achieved. Of those infected, <5% will develop the chronic form of disease. The age at which one is infected dictates the risk of developing chronic disease. Chronicity is the most serious outcome of disease as it can result in cirrhosis or liver cancer. The likelihood of hepadnavirus-associated carcinoma is greatest in animals (and humans) infected at birth. Hepatocellular carcinoma is 100 times more likely to develop in a chronically infected individual than in a noncarrier. The viral determinant for cellular transformation has yet to be determined. Many individuals are asymptomatic until complications emerge related to chronic carriage.
[0146] HBV has a small DNA genome that, upon infection, is transported to the nucleus and forms episomal cccDNA, the template for all viral transcripts. Initially, HBV replicates in all hepatocytes while evading immune surveillance. After decades of infection, the immune system eventually recognises HBV-infected cells and attacks them. The resultant inflammation kills most, but not all, infected hepatocytes. This immune attack drives ongoing liver injury.
[0147] The inventors of the present disclosure have confirmed that natural liver turnover clears HBV infected liver cells, and showed that a single round of mitosis clears HBV covalently closed circular DNA (cccDNA), the template for pgRNA that generates new viruses, resulting in two uninfected daughter cells. However, despite the combination of long-term antiviral therapy and substantial liver cell turnover, HBV-infected cells persist. The ability to cure chronic hepatitis remains a priority in the field.
[0148] In some examples, the Hepadnavirus is HBV.
[0149] In some examples, the Hepadnavirus is domestic cat hepatitis (DCH).
[0150] In some examples, the Hepadnavirus is equine hepatitis (EqHBV).
[0151] In some examples, the Hepadnavirus is canine hepatitis (ICH).cccDNA and viral
[0152]
[0153] HBV persistence is due to the stability of existing cccDNA, as antiviral therapies prevent formation new cccDNA. Current hepatitis B therapies block HBV replication, but cccDNA genomes are unaffected. To cure chronic hepatitis B, all cccDNA must be cleared.
[0154] While many of the infected cells are killed by immune-mediated cell death, mathematical models show that HBV clearance requires mitosis of infected cells to form two uninfected daughter cells. As used herein, the term “clearance”, “clearing”, and “clear” and related terms in respect of clearing an infection, clearing viral infected cells, or clearing cccDNA or similar contexts refers to the reduction, removal, or elimination of the infection, virally infected cells, or cccDNA. Clearance may be partial, for example, 50% clearance, 60% clearance, 70% clearance, 80% clearance, 90% clearance, 95% clearance, or 99% clearance. For example, the number of senescent cells infected by HBV in the subject is reduced by more than 50%. Clearance may be total, for example 100% clearance or complete elimination.
[0155] However, despite long-term antiviral therapy (which suppresses viral replication and new infections) and liver cell turnover (leading to the loss of infected cells), HBV infected cells persist and increased liver cancer risk is maintained. The present inventors have discovered a subset of cells that resists mitosis and harbour cccDNA. The present invention is based on the identification of this subset of cells and on specifically targeting this population of persistent infected cells, for example to treat / prevent chronic infection, to monitor infection, to diagnose chronic infection, to determine efficacy of treatment of chronic infection, as a predictor of disease associated with chronic infection, for example but not limited to cancer, to determine suitability of a proposed treatment regime, and / or to determine suitability of participation in a clinical trial targeting chronic viral infection.
[0156] As current antiviral treatments are insufficient for total clearance of the virus, targeting the subset of cells identified by the present inventors could be a treatment option on the path to a complete cure of HBV. Moreover, this reservoir provides potential new information on HBV pathogenesis and insight into progression onto HCC development. Chronic low level viral activity, and induced alterations into host cell metabolism and cell kinetics could contribute to oncogenesis. The mere existence of these cells indicates a method of immune evasion such as the generation of a senescence associated secretory phenotype (SASP), which alters cellular microenvironment to shield these reservoir cells from immune detection.The present inventors have established a novel pathway for cccDNA survival in host hepatocytes, utilising host mechanics of cell arrest in favour of the HB V persistence. These HBV reservoir cells survive mitosis through cell arrest and may potentially evade immune clearance via secretion of a SASP. Current treatment options suppressing HBV replication insufficient as treatment cessation will allow for these cells to reinfect the liver. The present inventors have identified these cells to be positive for p53, betagalactosidase and lipofuscin, which are all markers of cellular senescence, and have characterised their transcriptome for modulation of several pathways of cell arrest.
[0157] In some examples, provided herein is a method of treating or preventing a cccDNA virus infection in a subject suffering therefrom. For example, a chronic cccDNA virus infection. As used herein, the term “cccDNA virus” refers to any virus that comprises a cccDNA. For example, a hepadnavirus. For example, HBV.
[0158] In some examples, provided herein is a method of treating or preventing a Hepadnavirus infection in a subject suffering therefrom. In some examples, provided herein is a method of treating or preventing a HBV infection in a subject suffering therefrom. In some examples, the infection is chronic.
[0159] Senescent reservoir cells harbouring viral cccDNA
[0160] The present inventors have established that HBV cccDNA is lost during hepatocyte mitosis. As disclosed herein, the present inventors have now identified a unique sub-population of “hibernating” liver cells which maintain virus cccDNA. The present inventors have demonstrated that these cells do not undergo mitosis, and are in a state of senescence. Without mitosis, the cells are not naturally cleared, and instead remain in the liver of subjects previously infected with HBV, causing chronic infection. This subset of senescent reservoir cells must be eliminated to cure chronic HBV. cccDNA harbouring is not limited to only HBV specifically, but rather, the present inventors have demonstrated that the principle applies to all types of cccDNA, which can be harboured in a senescent cell of any type that the cccDNA might naturally find its way into, for example during an acute infection.
[0161] The present inventors have identified that the persistently infected cells upregulate senescence-associated pathways, including peptidase activity and triglyceride metabolism. Without being bound by theory, the present inventors have identified that senescent infected cells act as reservoirs to maintain viral infection by not undergoing mitosis and evading the antiviral immune response. Accordingly, in some embodiments, the present invention provides a method of treating or preventing a Hepadnavirusinfection in a subject suffering therefrom, comprising specifically targeting this population of reservoir cells.
[0162] The present inventors have further demonstrated that several small molecule drugs can eliminate reservoir cells. In some examples, the small molecule drug is DT2216, a small molecule drug that eliminates senescent cells.
[0163] In some examples, provided herein is a method of treating or preventing a hepadnavirus infection in a subject suffering therefrom, comprising administering to the subject a selective inhibitor of one or more senescence-associated proteins. As used herein, the term “senescence-associated protein” refers to any protein that is involved in one or more pathways that are activated during the senescence process of a cell. For example, activation of senescence pathways is known to decreases or inhibits the cell's capability to induce, and ultimately undergo apoptosis. Accordingly, one example of a senescence-associated protein of the present disclosure is a protein involved in an apoptosis pathway, and which is affected or regulated, for example, inhibited or upregulated, by induction of senescence pathways.
[0164] In some examples, the senescence-associated protein is a BCL-2 family protein. In some examples, provided herein is a method of monitoring disease progression in a subject with hepadnavirus infection, the method comprising: i) detecting the presence of one or more markers of cell senescence and determining a level of senescent hepadnavirus infected cells in a sample taken from a subject; and ii) comparing that level to a reference level; wherein a higher level in the subject sample is indicative of disease progression, and a lower level in the subject sample is indicative of disease regression.
[0165] In some examples, provided herein is a method of screening a subject with HBV for a clinical trial, wherein a subject is included in the clinical trial if the presence of one or more markers of cell senescence is detected in a sample taken from the subject. For example, clinical trial is a trial for treatment of HBV.
[0166] In some examples, provided herein is method of prognosing or determining a likelihood that a subject with chronic hepadnavirus infection will respond well to a treatment regime, the method comprising: i) detecting the presence of one or more markers of cell senescence and determining a level of senescent hepadnavirus infected cells in a sample taken from a subject; and ii) comparing that level to a reference level; wherein a higher level in the subject sample is indicative of reduced treatment efficacy, and a lower level in the subject sample is indicative of increased treatment efficacy.
[0167] In some examples, a senescent cell is one with a senescence associated secretory phenotype (SASP).Viral cccDNA detection
[0168] In one example, the methods of the present disclosure comprise a step of detecting viral cccDNA in a sample. Any suitable detection method may be used, and the skilled person will be aware of several suitable detection methods, including those described herein. For example, the detection method comprises PCR, for example cinqPCR, for example, pan-genomic cinqPCR. For example, the detection method comprises immunohistochemistry. For example, the detection methods comprises immunohistology. For example, the detection method comprises southern blot.
[0169] In one example, provided herein is a method for detecting the presence or absence of a chronic infection in a subject, the method comprising detecting the presence or absence of a marker of viral cccDNA in a sample obtained from a subject.
[0170] In one example, provided herein is a method for detecting the presence or absence of a senescent reservoir of infected cells in a subject, the method comprising detecting the presence or absence of viral cccDNA in a biological sample obtained from a subject.
[0171] In one example, provided herein is a method of monitoring an infection in a subject, comprising comparing the number of detected cells harbouring viral cccDNA and / or the amount of detected cccDNA with a pre-determined amount, and wherein a difference in the amount between the number of detected cells harbouring viral cccDNA and / or the amount of detected cccDNA and pre-determined amount is indicative of a change in status of the infection in the subject.
[0172] In one example, provided herein is a method of predicting a subject’s response to a treatment regime, for example a regime comprising viral therapy, wherein the method comprises comparing the number of detected cells harbouring cccDNA / amount of detected cccDNA with a pre-determined amount, and wherein a difference in the amount between the sample cccDNA amount and the pre-determined amount is indicative of a likely response of the subject to the treatment regime.
[0173] In one example, the pre-determined amount is an amount detected in a reference sample. For example, a greater number of cells harbouring cccDNA / amount of cccDNA in the sample compared to the pre-determined amount is indicative of infection progression in the subject, and a smaller number of cells harbouring cccDNA / amount of cccDNA in the sample compared to the pre-determined amount is indicative of infection regression in the subject. For example, a lower number of cells harbouring cccDNA / amount of cccDNA than a pre-determined amount is indicative of a likely positive response to a treatment regime. For example, a higher number of cells harbouring cccDNA / amount of cccDNA than a pre-determined amount is indicative of a likely negative response to, or reduced efficacy of a treatment regime. For example, thenumber of cells harbouring cccDNA / amount of cccDNA can be used to predict likelihood of complications such as development of a disease or condition associated with chronic hepadnavirus infection, such as, for example, liver cirrhosis or cancer in a subject. For example, the number of cells harbouring cccDNA / amount of cccDNA can be used as a prognostic factor of chemosensitivity. For example, the number of cells harbouring cccDNA / amount of cccDNA can be used as a prognostic factor for therapeutic decision-making. For example, the predetermined amount is a sample taken from the same subject at an earlier time point. For example, the pre-determined amount is a sample taken before treatment, for example, with antivirals and / or interferon, and the number of cells harbouring cccDNA / amount of cccDNA is an amount after treatment. For example, a change in the amount of number of cells harbouring cccDNA / amount of cccDNA in the sample and second sample is indicative of a change to the status of the infection in the patient. For example, a lower number of cells harbouring cccDNA / amount of cccDNA than a pre-determined amount is indicative of a positive response to treatment. For example, a higher number of cells harbouring cccDNA / amount of cccDNA than a pre-determined amount is indicative of a negative or no response to treatment.
[0174] In one example, provided herein is an assay for detecting the presence or absence of cells harbouring cccDNA / cccDNA in a sample from a subject comprising the methods described herein, for example, pan-genomic cinqPCR.
[0175] Senolytic agents
[0176] Senolytics are a class of drugs that selectively clear senescent cells. The first senolytic drugs include Dasatinib, Quercetin, Fisetin, and Navitoclax, and operate by targeting different features of senescent cells. Senescent cells typically accumulate with ageing and at causal sites of multiple chronic disorders, including diseases accounting for the bulk of morbidity, mortality and health expenditures. The most deleterious senescent cells are resistant to apoptosis and have up-regulation of anti-apoptotic pathways which defend senescent cells against their own inflammatory senescence-associated secretory phenotype, allowing them to survive, despite killing neighbouring cells. In some instances, senolytics transiently disable these defence mechanisms, leading to clearing of senescent cells. For a recent review, see, e.g. Kirkland and Tchkonia 2020.
[0177] In some embodiments, senolytics useful in the methods and compositions described herein include those listed in Table 5. These senolytics target Bcl-2 family proteins, Src family non-receptor tyrosine kinases, heat shock protein-90 and glutaminase. In some embodiments, senolytic agents include, for example, MDM2 (E3ubiquitin-protein ligase) inhibitors (e.g., nutlin 3a, RG-7112). In some embodiments, senolytic agents include Akt specific inhibitors (e.g., MK-2206).
[0178] Src family
[0179] Src is a family of non-receptor tyrosine kinases that are involved in various cellular processes including proliferation and survival, as well as regulation of senescence via downstream activation of PI3K / AKT and MAPK pathways. The most well known inhibitor of this family is Dasatinib, which is often paired with Quercetin, a nonspecific inhibitor of kinase inhibitor as a combination therapy.
[0180] Heat shock protein 90 (HSP-90)
[0181] Heat shock protein 90 (HSP-90) is a molecular chaperone which plays a key role in stabilisation of client proteins, many of which are damaged or misfolded in senescence, as well as several anti-apoptotic factors such as Bcl-2. Inhibition of this pathway therefore would increase this proteotoxic stress to selectively kill senescent cells. An example of an HSP90 inhibitor is Alvespimycin.
[0182] Glutaminase
[0183] Glutaminase is an enzyme which catalyses the conversion of glutamine to glutamate, an essential step in cellular metabolism. Due to the metabolic changes that occur in senescence, cells have an increased requirement for glutaminolysis mediated production of ammonia, in order to avoid lethal intracellular acidosis from lysosomal membrane damage. Examples of glutaminase inhibitors include BPTES and Telaglenastat, both small molecule non-competitive inhibitors of glutaminase.
[0184] BCL-2 family proteins
[0185] This group of proteins is and are known to regulate cellular apoptosis. Apoptosis can be triggered through either an extrinsic pathway, activated by cell surface death receptors, or an intrinsic pathway, which is initiated by developmental signals and various internal stresses. The intrinsic pathway, also referred to as the stress or mitochondrial pathway, is mainly controlled by the BCL-2 family — key regulators of caspase activation. This family includes anti-apoptotic (pro-survival) proteins with BH1-BH4 domains, such as BCL-2, BCL-xL, BCL-w, Al, MCL-1, and BCL-B, along with pro-apoptotic proteins containing BH1, BH2, and BH3 domains, like BAX, BAK, and BOK, and pro-apoptotic BH3-only proteins, including BIK, BAD, BID, BIM, BMF, HRK, NOXA, and PUMA. The anti-apoptotic BCL-2 proteins inhibit the activation ofmulti-domain pro-apoptotic proteins like BAX and BAK. While the precise mechanism of apoptosis regulation remains unclear, it is believed that BH3-only proteins, activated by intracellular stress signals, bind to anti-apoptotic BCL-2-like proteins. This binding occurs through a BH3 ligand-receptor binding, wherein the BH3 -binding groove formed by the BH1-3 regions on anti-apoptotic proteins, effectively neutralising them. As a result, BAX and BAK can oligomerise in the mitochondrial membrane, causing membrane permeabilisation, cytochrome C release, caspase activation, and, ultimately, apoptosis.
[0186] B-cell lymphoma-2 (BCL-2) family proteins regulate programmed cell death and are divided into 3 subcategories, anti-apoptotic, pro-apoptotic effector and pro-apoptotic BH3-only proteins. Some members of the family (such as BCL-2 and BCL-XL) inhibit apoptosis, whereas others (such as BAX and BAK) promote cell death. BCL-2 family proteins, which have either pro- or anti-apoptotic activities, have been studied intensively for the past decade owing to their importance in the regulation of apoptosis, tumorigenesis and cellular responses to anti -cancer therapy. They control the point of no return for clonogenic cell survival and thereby affect tumorigenesis and host-pathogen interactions and regulate animal development.
[0187] Members of the BCL-2 family regulate apoptosis in mammals, reptiles, amphibs, fish, and other phyla of metazoan life, with exception of nematodes and insects. Their molecular structure and function, as well as their protein dynamics, are highly conserved.
[0188] Bcl-2 family proteins are characterised the presence of one or more Bcl-2 Homology (BH) domains, and have a general structure that consists of a hydrophobic a-helix surrounded by amphipathic a-helices. Some members of the family have transmembrane domains at their c-terminus which primarily function to localise them to the mitochondrion. The BH3-only subset of the Bcl-2 family of proteins contain only a single BH3-domain. The BH3-only members play a key role in promoting apoptosis. BCL-2 family proteins control senescent secretome, and understanding the role of BCL-2 proteins in senescence is a current focus of research. It has been known that BCL-2 proteins participate in control of the cell-cycle, but BCL-2 anti-apoptotic proteins could also participate in proliferation arrest of senescent cells. Interestingly, recent advances led to the development of molecules that mimic the BH3 motifs of pro-apoptotic proteins, known as BH3 mimetics. Drugs known as BH3 mimetics are antagonists for the anti-apoptotic Bcl-2 members in order to induce apoptosis and include drugs such as Navitoclax, Venetoclax, ABT-737, Sabutoclax, Obatoclax and Gambogic Acid. For example, Navitoclax (also known as ABT-263), specifically binds to the hydrophobic pockets of BCL-2, BCL-XL and BCL-W to block their activity.In some examples, the senescence associated proteins are selected from the group consisting of BCL-2, BCL-XL, BCL-W, MCL-1, BFL-1 / A1, and BCL2L10 or their relevant orthologues or senescence-associated isoforms of any one thereof. For example, the senescence associated protein is BCL-2 or an anti-apoptotic isoform thereof. For example, the senescence associated protein is BCL-XL or its orthologue or a senescence-associated isoform thereof. For example, the senescence associated protein is BCL-W or its orthologue or a senescence-associated isoform thereof. For example, the senescence associated protein is MCL-1 or its orthologue or a senescence-associated isoform thereof. For example, the senescence associated protein is BFL-1 / A1 or its orthologue or a senescence-associated isoform thereof. For example, the senescence associated protein is BCL2L10 or its orthologue or a senescence-associated isoform thereof.
[0189] In some examples, the selective inhibitor of the senescence-associated BCL-2 family protein is a selective inhibitor of BCL-2 / BCL-XL, a selective inhibitor of BCL-2 / BCL-XL / BCL-W, or a selective inhibitor of BCL-XL. For example, a selective inhibitor of BCL-2 / BCL-XL. For example, a selective inhibitor of BCL-2 / BCL-XL / BCL-W. For example, a selective inhibitor of BCL-XL.
[0190] In some examples, the selective inhibitor of the senescence-associated BCL-2 family protein is selected from a small molecule inhibitor, an oligonucleotide inhibitor, a polynucleotide inhibitor, a peptide inhibitor, and a protein inhibitor. For example, the selective inhibitor is a small molecule inhibitor. For example, the selective inhibitor is an oligonucleotide inhibitor. For example, the selective inhibitor is a polynucleotide inhibitor. For example, the selective inhibitor is a peptide inhibitor. For example, the selective inhibitor is a protein inhibitor.
[0191] For example, small molecule inhibitors include benzothiazole-hydrazone small molecule inhibitors, for example, BH3 mimetic WEHI-539 (5-[3-[4-(aminomethyl)phenoxy]propyl]-2-[(8E)-8-(l ,3-benzothiazol-2-ylhydrazinylidene)-6,7-dihydro-5H-naphthalen-2-yl]- 1 ,3-thiazole-4-carboxylic acid), aBH3 peptide mimetic.
[0192] For example, the selective inhibitor is an aminopyridine compound. An aminopyridine compound that may be used as a selective BCL-xL inhibitor is BXI-61 (3-[(9-amino-7-ethoxyacridin-3-yl)diazenyl]pyridine-2,6-diamine).
[0193] For example, the selective inhibitor is a benzimidazole compound. An example of a benzimidazole compound that may be used as a selective BCL-XL inhibitor is BXI-72 (2'-(4-Hydroxyphenyl)-5-(4-methyl-l-piperazinyl)-2,5'-bi(lH-benzimidazole) trihydrochloride).
[0194] For example, the selective inhibitor is a tetrahydroquinoline compound, for example a tetrahydroisoquinoline amide substituted phenyl pyrazole.For example, the selective inhibitor is a phenoxyl compound. An example of a phenoxyl compound that may be used as a selective BCL-xL inhibitor is 2[[3-(2,3-di chlorophenoxy) propyl]amino]ethanol (2,3-DCPE).
[0195] For example, the selective inhibitor is a quinazoline sulfonamide compound. For example, the selective inhibitor is any small molecule known in the art, for example but not limited to, those referred to in WO2015116740.
[0196] In some examples, the selective inhibitor is selected from the group consisting of: Navitoclax (ABT-263), A-1551852, A-1331852, A-1155463, A-1155463 dihydrochloride, A-1210477, Venetoclax (ABT-199), ABT-737, Sonrotoclax (BGB-11417), S63845, S64315 (MIK665), S55746 (BCL201), AZD5991, AZD4320, BT-1197, AMG-176, WEHI-539, IS21, Obatoclax Mesylate (GX15-070), Subatoclax (BI-97C1), Maritoclax (Marinopyrrole A), TW-37, UMI-77, BDA-366, BM-1252, BXI-61, BXI-72, HA14-1, BDA366, APG-2575 (lisaftoclax), BH3I-1, DT2216, VU661013, a perylene quinone mycotoxin (e.g., Altertoxin I, Altertoxin II, and alterperylenol from Alternaria alternata) and derivatives thereof, gossypol and enantiomers thereof, AT-101, siRNA, Oblimersen, and tetrocarcin A secreted by Micromonospora sp.
[0197] In some examples, the selective inhibitor is Navitoclax or A-1331852 or A-1155463 or A-1155463 dihydrochloride or WEHI-539. For example, the selective inhibitor is Navitoclax. For example, the selective inhibitor is A-1331852. For example, the selective inhibitor is A-1155463. For example, the selective inhibitor is A-1155463 dihydrochloride. For example, the selective inhibitor is Venetoclax (ABT-199). For example, the selective inhibitor is ABT-737. For example, the selective inhibitor is Sonrotoclax (BGB-11417). For example, the selective inhibitor is S63845. For example, the selective inhibitor is AZD5991. For example, the selective inhibitor is AZD4320. For example, the selective inhibitor is BT-1197. For example, the selective inhibitor is AMG-176. For example, the selective inhibitor is WEHI-539. For example, the selective inhibitor is IS21. For example, the selective inhibitor is Obatoclax (GX15-070). For example, the selective inhibitor is Subatoclax. For example, the selective inhibitor is Maritoclax. For example, the selective inhibitor is TW-37. For example, the selective inhibitor is UMI-77. For example, the selective inhibitor is BDA-366. For example, the selective inhibitor is BM-1252. For example, the selective inhibitor is BXI-61. For example, the selective inhibitor is BXI-72. For example, the selective inhibitor is a perylene quinone mycotoxin and / or a derivative thereof. For example, the selective inhibitor is Altertoxin I. For example, the selective inhibitor is Altertoxin II. For example, the selective inhibitor is alterperylenol). For example, the selective inhibitor is gossypol and / or enantiomers thereof. For example, the selective inhibitor is AT-101. For example,the selective inhibitor is siRNA. For example, the selective inhibitor is Oblimersen. For example, the selective inhibitor is tetrocarcin A. For example, the selective inhibitor is A-1210477. For example, the selective inhibitor is S64315 (MIK665). For example, the selective inhibitor is S55746 (BCL201). For example, the selective inhibitor is HA14-1. For example, the selective inhibitor is BDA366. For example, the selective inhibitor is APG-2575 (lisaftoclax). For example, the selective inhibitor is BH3I-1, DT2216. For example, the selective inhibitor is VU661013. For example, the selective inhibitor is a combination of any of the foregoing. For example, the selective inhibitor is one or more of Navitoclax, A-1331852, A-1155463, A-1155463 dihydrochloride, and WEHI-539.
[0198] In some examples, the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is an oligonucleotide or polynucleotide. As used herein, the term “polynucleotide”, “nucleotide sequence” or “nucleic acid sequence” will be understood to mean a series of contiguous nucleotides (or bases) covalently linked to a phosphodiester backbone. By convention, sequences are presented from the 5' end to the 3' end, unless otherwise specified.
[0199] In some examples, the oligonucleotide or polynucleotide is an RNA interference (RNAi) molecule, for example, Oblimersen.
[0200] In some examples, the selective inhibitor is used in combination with a further agent, for example, to increase the potency and / or efficacy of the inhibitor. For example, in combination with a chemotherapy. For example, in combination with any one or more of Gemcitabine, Oxaliplatin, Cisplatin, Doxorubicin (or pegylated liposomal doxorubicin), 5 -fluorouracil (5-FU), Capecitabine, and Mitoxantrone. Choice of suitable combination therapy is well-within the skill of a clinician in the field, and will depend on patient-specific factors, including but not limited to co-morbidities, types of e.g. cancer to be treated, and contra-indications.
[0201] Methods and assays
[0202] As described herein, the present disclosure relates generally to methods and compositions for treating and / or preventing a cccDNA viral infection, for example, a Hepadnavirus infection, for example, a hepatitis B virus (HBV) infection in a subject, and methods of screening, diagnosing, and / or monitoring subjects with a cccDNA viral infection, for example a Hepadnavirus infection, for example, a hepatitis B virus (HBV) infection.
[0203] The present disclosure includes a new, sensitive method to quantify the episomal covalently closed circular (ccc)DNA, for example of hepadnavirus, for example of HBV. The inability to sensitively and accurately quantify the episomal virus DNA has been oneof the major factors holding back research into the basic virology and cures for viruses which utilise cccDNA, including hepadnaviruses, for example, HBV, and chronic HBV infection. The present inventors have determined a way to overcome the poor discrimination between the relatively rare cccDNA forms (1-10 copies per cell) and the high levels (100s per cell) of replicative intermediate DNA, which have identical sequences but slightly different structures, using a new polymerase chain reaction (PCR)-based assay. An added advantage of the PCR method of the present invention is that it preserves cellular DNA, unlike all other previous PCR-based methods. In some examples, provided herein is an assay to quantify episomal cccDNA. In some embodiments, the methods of the present disclosure include the assays described herein.
[0204] In some examples, the assay quantifies episomal cccDNA of a hepadnavirus. In some examples, the assay quantifies episomal cccDNA of HBV. In some examples, the assay has specificity and sensitivity. In some examples, the assay requires only 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 copies of viral cccDNA per PCR. For examples, the assay requires between 1 and 10 copies of cccDNA. For example, the assay requires at least one copy of viral DNA. For example, the assay requires one or more copies of viral cccDNA. In some examples, the assay can detect and / or quantify cccDNA in less than 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, or 10000 cells. In some examples, the assay can detect cccDNA in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 cells. In some examples, the assay can detect and / or quantify cccDNA in a sample comprising less than 20 cells. In some examples, the assay can detect and / or quantify cccDNA in a sample comprising less than 5 cells.
[0205] Patients who spontaneously clear cccDNA virus infected cells, for example patients who spontaneously clear HBV infected liver cells, have very low cccDNA in cells during latent chronic infection. Accordingly, a highly sensitive assay for detecting cccDNA in as few as less than five cells from a patient tissue sample is a significant advantage.
[0206] In some examples, the assay preserves cellular DNA. In some examples, the assay distinguishes between cccDNA and other cellular DNA, including but not limited to other replicative intermediate DNA. In some examples, the assay distinguishes between identical HBV DNA sequences with different structural forms. For example, different structural forms for different genotypes. In some examples, the assay distinguished between identical HBV DNA sequences for all genotypes, for example between different genotypes. In some examples, the assay is suitable for use on clinical samples. In some examples, use of the assay and methods described herein provides a valuable output for clinical trials of anti-HBV therapies. In some examples, use of the assay and methodsdescribed herein provides a valuable output for directly influencing health decisions in clinical care of chronic HBV infection. For example, to diagnose chronic infection, for example to identify suitable treatments, for example to determine efficacy of a treatment regime, for example to predict likelihood of disease associated with chronic infection, for example to determine suitability for inclusion in a clinical trial, for example to monitor HBV disease and / or infection progression in a subject., for example HBV.
[0207] In some examples, the method of the disclosure relies on data previously obtained or provided (e.g., by a third party) relating to the level of chronic infection of a cccDNA virus. In this regard, the skilled person will appreciate that the methods of the disclosure needn’t involve the step(s) of obtaining the biological sample and / or quantifying or determining a level of expression of cccDNA in that sample, for example HBV cccDNA. These and similar steps may be performed by one or more third parties, with the resultant data on the presence, level, distribution etc of cccDNA in a sample then being provided in order to perform a method of treatment, prognosis, diagnosis, or any other method as described herein. However, in other examples, the person(s) performing the method of the disclosure also obtains the biological sample from the subject and / or determines the presence, level, distribution etc of cccDNA in the biological sample. Accordingly, the method described herein may comprise performing one or more assays on the biological sample obtained from a subject to determine the presence, level, distribution etc of cccDNA therein. Any method known in the art for detecting and / or measuring the presence, level, distribution etc of cccDNA in a biological sample may be used, including but not limited histological staining, immunohistochemistry, PCR, cccDNA PCR assays including cinqPCR, southern blot hybridisation.
[0208] As used herein, the terms, “prognosis”, “prognosing” and variants thereof shall refer to the prediction that a subject infected with a cccDNA virus will response well to a treatment regime, and / or will develop one or more diseases or conditions as the result of a chronic infection. Based on this prognosis, subjects may be stratified, for example into one of two or more clinical outcome groups, or, for example, into two groups defined as those suitable for participation in a clinical trial and those not suitable for participation in a clinical trial. Accordingly, the term “stratify”, “stratifying” or variants thereof as used herein, shall be understood in the context of the disclosure to mean categorising subjects with cccDNA viral infection into different categories relevant to the variable being analysed.
[0209] The term “reference level”, as used in the context of quantifying or determining a level of cccDNA virus infection, shall be understood to mean a pre-determined level of cccDNA. For example, a predetermined level may be obtained from:(i) a biological sample from a normal or healthy subject;
[0210] (ii) a biological sample from a subject not suffering from a chronic cccDNA viral infection, e.g. HBV;
[0211] (iii) a biological sample from the subject prior to viral infection;
[0212] (iv) an extract of any of (i) to (iii);
[0213] (v) a data set comprising levels of determined from any one of (i) to (iv);
[0214] (vi) a data set comprising levels from the subject not infected, or a population of subjects not infected; and
[0215] (vii) a data set comprising levels of expression from the subject prior to viral infection, for example, infection with HBV.
[0216] The term “status” shall be taken to include whether or not a subject has a chronic viral infection, and a ranking or determination relevant to the variable being assessed.
[0217] Analysis as described in the preceding paragraphs can also consider clinical parameters or traditional laboratory risk factors.
[0218] Information as discussed above can be combined and made more clinically useful through the use of various formulae, including statistical classification algorithms and others, combining and in many cases extending the performance characteristics of the combination beyond that of any individual data point. These specific combinations show an acceptable level of prognostic accuracy, and, when sufficient information from the biomarker is combined in a trained formula, often reliably achieve a high level of prognostic accuracy transportable from one population to another.
[0219] Any formula may be used to convert differential expression level results for chronic infection of a cccDNA virus into indices or indexes useful in the practice of the disclosure. As indicated herein, and without limitation, such indices may indicate, among the various other indications, whether or not a subject who has been infected with a cccDNA virus will suffer from chronic disease or symptoms or not. In some examples, provided herein is a method of determining the likelihood that a subject previously infected with a hepadnavirus will suffer from chronic disease, for example liver cirrhosis and / or cancer.
[0220] The actual model type or formula used may itself be selected from the field of potential models based on the performance and diagnostic accuracy characteristics of its results in a training population. The specifics of the formula itself may commonly be derived from biomarker results in the relevant training population. Amongst other uses, such formula may be intended to map the feature space derived from one or more biomarker inputs to a set of subject classes (e.g. useful in predicting class membership of subjects as being likely to respond to a specific treatment regime or unlikely to respondto a specific treatment regime), to derive an estimation of a probability function of likelihood using a Bayesian approach (e.g. the likelihood of effective treatment), or to estimate the class-conditional probabilities, then use Bayes' rule to produce the class probability function as in the previous case.
[0221] Following analysis and determination of an index of probability for any of the methods and variables described herein, the index can be transmitted or provided to a third party, e.g., a medical practitioner for assessment. The index may be used by the practitioner to assess whether or not additional diagnostic methods are required, and / or what treatment / clinical management may be required.
[0222]
[0223] In some examples, provided herein is a pharmaceutical composition comprising the selective inhibitor of one or more senescence-associated proteins for treating or preventing a hepadnavirus infection. For example, for treating or preventing HBV infection. For example, for treating or preventing chronic HBV. In one example, the composition comprises the selective inhibitor of one or more senescence-associated proteins and a pharmaceutically acceptable carrier. The selective inhibitor of one or more senescence-associated proteins may be used in the manufacture of a medicament for treating or preventing a hepadnavirus infection, or a disease or symptom associated with a hepadnavirus infection. Compositions may be used for treating, preventing and / or delaying progression of a disease or condition in a subject. For example, the selective inhibitor of one or more senescence-associated proteins is used to treat a disease or condition. For example, selective inhibitor of one or more senescence-associated proteins is used to prevent a disease or condition. For example, the selective inhibitor of one or more senescence-associated proteins is used to delay progression of a disease or condition. For example, the disease or condition is a disease or condition associated with chronic cccDNA virus infection. For example, the disease or condition is chronic HBV. For example, the disease or condition is liver cirrhosis. For example, the disease or condition is cancer, for example a solid tumour cancer, for example, a liver cancer, for example, a cancer that has developed as a result of metastasis of a liver cancer.
[0224] In some examples, provided herein is a method of treating a cccDNA virus- associated disease or condition in a subject, the method comprising administering to the subject the selective inhibitor of one or more senescence-associated proteins. In one example, provided herein is a method of preventing a cccDNA virus-associated disease or condition in a subject, the method comprising administering to the subject the selective inhibitor of one or more senescence-associated proteins. In some examples, providedherein is a method of delaying progression of a cccDNA virus-associated disease or condition in a subject, the method comprising administering to the subject the selective inhibitor of one or more senescence-associated proteins.
[0225] In some examples, the composition comprises Navitocl ax. In some examples, the composition comprises A-1551852. In some examples, the composition comprises A-1155463. In some examples, the composition comprises A-l 155463 dihydrochloride. In some examples, the composition comprises WEHI-539. In some examples, the composition comprises both Navitoclax and A-1551852. In some examples, the composition comprises one or more of Navitoclax, A-1331852, A-l 155463, A-l 155463 dihydrochloride, and WEHI-539.
[0226] Suitable routes of administration will be apparent to the skilled person, and include intravenous, intramuscular, subcutaneous, or intraperitoneal injection, oral administration, and / or topical administration.
[0227] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins decreases expression of HBV cccDNA in the subject.
[0228] In some examples, the selective inhibitor of one or more senescence-associated proteins is administered as an injection. For example, an intravenous injection. For example, an intramuscular injection. For example, a subcutaneous injection. For example, an intraperitoneal injection.
[0229] In some examples, the selective inhibitor of one or more senescence-associated proteins is administered orally.
[0230] In some examples, the selective inhibitor of one or more senescence-associated proteins is administered topically.
[0231] The pharmaceutical compositions may be in unit dosage forms suitable for single administration of precise dosages. In unit dosage form, the formulation is divided into unit doses containing appropriate quantities of one or more compound. The unit dosage may be in the form of a package containing discrete quantities of the formulation. Nonlimiting examples include aqueous suspension compositions packaged in single-dose non-reclosable (or resealable) containers. Alternatively, multiple-dose reclosable (or resealable containers can be used, in which case it is typical to include a preservative in the composition. By way of example only, formulations for parenteral injection may be presented in unit dosage form, which include, but are not limited to ampoules, or in multidose containers, with an added preservative.
[0232] In some examples, cccDNA is decreased in the subject by at least 2-fold, by at least 3 -fold, or by at least 4-fold, relative to the level of cccDNA expression prior toadministration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins. For example, cccDNA is decreased between 2-fold and 8-fold, between 2 -fold and 7-fold, between 2-fold and 6-fold, between 2-fold and 5-fold, between 2-fold and 4-fold. For example, HBV cccDNA is decreased.
[0233] In some examples, administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins reduces the number of senescent cells infected by HBV in the subject relative to the number of senescent cells infected by HBV in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0234] Combination therapies
[0235] In some examples, a selective inhibitor of one or more senescence-associated proteins is administered in combination with a further treatment or treatment regime. For example, the selective inhibitor of one or more senescence-associated proteins is administered prior to the further treatment or treatment regime. For example, the selective inhibitor of one or more senescence-associated proteins is administered simultaneously with or approximately contemporaneously with the further treatment or treatment regime. For example, the selective inhibitor of one or more senescence-associated proteins is administered after the further treatment or treatment regime.
[0236] In some examples, the further treatment or treatment regimens comprises a second senescence associated pathway inhibitor. For example, an inhibitor of a senescence associated protein. For example, a second BCL-2 family protein inhibitor. For example, a combination treatment comprises a second selective inhibitor of one or more senescence-associated BCL-2 family proteins. For example, a further treatment of treatment regime comprises an inhibitor selected from: Navitoclax (ABT-263), A-1551852, A-1331852, A-1155463, A-1155463 dihydrochloride, A-1210477, Venetoclax (ABT-199), ABT-737, Sonrotoclax (BGB-11417), S63845, S64315 (MIK665), S55746 (BCL201), AZD5991, AZD4320, BT-1197, AMG-176, WEHL539, IS21, Obatoclax Mesylate (GX15-070), Subatoclax (BL97C1), Maritoclax (Marinopyrrole A), TW-37, UML77, BDA-366, BM-1252, BXI-61, BXL72, HA14-1, BDA366, APG-2575 (lisaftoclax), BH3I-1, DT2216, VU661013, a perylene quinone mycotoxin (e.g., Altertoxin I, Altertoxin II, and alterperylenol from Altemaria altemata) and derivatives thereof, gossypol and enantiomers thereof, AT-101, siRNA, Oblimersen, and tetrocarcin A secreted by Micromonospora sp.In some embodiments, the selective inhibitor is Navitoclax, and the further treatment is one or more of A-1551852, A-l 155463, A-l 155463 dihydrochloride, DT2216 and WEHI-539.
[0237] In some embodiments, the selective inhibitor is A-1551852, and the further treatment is one or more of Navitoclax, A-l 155463, A-l 155463 dihydrochloride, DT2216 and WEHI-539.
[0238] In some embodiments, the selective inhibitor is A-l 155463 dihydrochloride, and the further treatment is one or more of A-l 155463, A-1551852, Navitoclax, DT2216, and WEHI-539.
[0239] In some embodiments, the selective inhibitor is WEHI-539, and the further treatment is one or more of A-1551852, A-l 155463 dihydrochloride, A-l 155463, DT2216 and Navitoclax.
[0240] In some embodiments, the selective inhibitor is A-l 155463, and the further treatment is one or more of A-1551852, A-l 155463 dihydrochloride, WEHI-539, DT2216 and Navitoclax.
[0241] In some embodiments, the selective inhibitor is DT2216, and the further treatment is one or more of A-1551852, A-l 155463 dihydrochloride, WEHI-539, A-l 155463, and Navitoclax.
[0242] In some examples, the further treatment or treatment regime comprises antiviral therapy. In some examples, the further treatment or treatment regime comprises antiviral therapy and interferon. In some examples, the further treatment or treatment regime comprises interferon. In some examples, the further treatment or treatment regime comprises a direct acting antiviral (DAA), for example, to reduce viral replication. In some examples, the further treatment or treatment regime comprises an immune modulator, for example, to induce greater antiviral immunity.
[0243] In some examples, the antiviral therapy comprises a nucleoside analogue.
[0244] In some examples, the antiviral therapy comprises one or more of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir), and adefovir (Hepsera). For example, the antiviral therapy comprises entecavir (Baraclude). For example, the antiviral therapy comprises tenofovir disaproxil fulmarate (Viread). For example, the antiviral therapy comprises tenofovir alafenamide (Vemlidy). For example, the antiviral therapy comprises lamivudine (Epivir). For example, the antiviral therapy comprises adefovir (Hepsera).
[0245] In some examples, the further treatment or treatment regimens comprises a chemotherapy. For example, a chemotherapeutic agent that treats hepatic carcinoma. For example, any one or more of Gemcitabine, Oxaliplatin, Cisplatin, Doxorubicin (orpegylated liposomal doxorubicin), 5 -fluorouracil (5-FU), Capecitabine, and Mitoxantrone.
[0246] In some examples, the selective inhibitor of one or more senescence-associated proteins described herein is administered in a topical formulation. For example, a composition comprising the selective inhibitor of one or more senescence-associated proteins described herein is applied in conjunction with surgery.
[0247] In general, other treatment agents do not necessarily have to be administered in the same pharmaceutical composition, and may, because of different physical and chemical characteristics, preferably be administered by different routes. For example, an antiviral therapy administered in combination with the selective inhibitor of one or more senescence-associated proteins may be delivered orally.
[0248] The determination of the mode of administration and the advisability of administration, where possible, in the same pharmaceutical composition as the selective inhibitor of one or more senescence-associated proteins is well within the knowledge of the skilled clinician. The initial administration of other agents in combination with the selective inhibitor of one or more senescence-associated proteins can be made according to established protocols known in the art, and then, based upon the observed effects, the dosage, modes of administration and times of administration can be modified by the skilled clinician.
[0249] The selective inhibitor of one or more senescence-associated proteins and an additional therapeutic agent may be administered concurrently (e.g., simultaneously, essentially simultaneously or within the same treatment protocol) or sequentially, depending upon the nature and phase of the symptoms or condition to be treated, the condition of the patient, and the actual choice of therapeutic agents used. The determination of the order of administration of the selective inhibitor of one or more senescence-associated proteins and any other additional treatment and the number of repetitions of administration of each therapeutic agent during a treatment protocol is well within the knowledge of the skilled physician after evaluation of the disease being treated, the condition of the patient, and the disclosures of the present application. It is known to those of skill in the art that therapeutically-effective dosages can vary when the drugs are used in treatment combinations. Methods for experimentally determining therapeutically-effective dosages of drugs and other agents for use in combination treatment regimens are described in the literature. For example, the use of metronomic dosing, i.e., providing more frequent, lower doses in order to minimise toxic side effects, has been described extensively in the literature. Combination treatmentfurther includes periodic treatments that start and stop at various times to assist with the clinical management of the patient.
[0250] For combination therapies, dosages of co-administered therapeutic agents will of course vary depending on the type of co-agents employed, the condition of the patient, and the condition to be treated.
[0251] In some examples, any other treatment may comprise several different treatments, which treatments may occur at different time points, and the selective inhibitor of one or more senescence-associated proteins may be given prior to, contemporaneously or after any one or more of those treatments as either a single dose or as several doses and / or on several different occasions.
[0252] In some examples, the combination treatment comprises at least one of an antiviral therapy and / or interferon. In one example, the combination treatment comprises interferon. In one example, the antiviral therapy comprises one or more of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir) and adefovir (Hepsera). In one example, the antiviral therapy comprises an inhibitor of viral replication. In one example, the antiviral therapy comprises a nucleoside analogue. For example, the nucleoside analogue inhibits viral replication. For example, the nucleoside analogue has minimal impact on HBsAg loss.
[0253] In some examples, the combination treatment comprises one or more of A-1551852, A-1155463 dihydrochloride, WEHI-539, A-l 155463, Navitoclax, andDT2216 and a nucleoside analogue. In some examples, the combination treatment comprises one or more of A-l 551852, A-1155463 dihydrochloride, WEHI-539, A-1155463, Navitoclax, and DT2216; and at least one of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir) and adefovir (Hepsera).
[0254] In some examples, the combination treatment comprises Navitoclax and a nucleoside analogue. In some examples, the combination treatment comprises Navitoclax and at least one of entecavir (Baraclude), tenofovir (Viread), lamivudine (Epivir) and adefovir (Hepsera).
[0255] In some examples, the combination treatment comprises DT2216 and a nucleoside analogue. In some examples, the combination treatment comprises DT2216 and at least one of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir) and adefovir (Hepsera).
[0256] In some examples, the combination treatment comprises A-l 551852 and a nucleoside analogue. In some examples, the combination treatment comprises A-1551852 and at least one of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir) and adefovir (Hepsera). In some examples, the combination treatment comprises A-l 155463 dihydrochloride and a nucleoside analogue. In some examples, the combination treatment comprises A-1155463 dihydrochloride and at least one of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir) and adefovir (Hepsera).
[0257] In some examples, the combination treatment comprises A-l 155463 and a nucleoside analogue. In some examples, the combination treatment comprises A-1155463 and at least one of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir) and adefovir (Hepsera).
[0258] In some examples, the combination treatment comprises WEHI-539 and a nucleoside analogue. In some examples, the combination treatment comprises WEHI-539 and at least one of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir) and adefovir (Hepsera).
[0259] In some examples, provided is a combination treatment comprising one or more of: i) the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is selected from the group consisting of Navitoclax (ABT-263), A-1551852, A-1331852, A-l 155463, A-l 155463 dihydrochloride, A-1210477, Venetoclax (ABT-199), ABT-737, Sonrotoclax (BGB-11417), S63845, S64315 (MIK665), S55746 (BCL201), AZD5991, AZD4320, BT-1197, AMG-176, WEHI-539, IS21, Obatoclax Mesylate (GX15-070), Subatoclax (BI-97C1), Maritoclax (Marinopyrrole A), TW-37, UMI-77, BDA-366, BM-1252, BXI-61, BXI-72, HA14-1, BDA366, APG-2575 (lisaftoclax), BH3I-1, DT2216, VU661013, a perylene quinone mycotoxin (e.g., Altertoxin I, Altertoxin II, and alterperylenol from Alternaria alternata) and derivatives thereof, gossypol and enantiomers thereof, AT-101, siRNA, Oblimersen, and tetrocarcin A secreted by Micromonospora sp.; and ii) an antiviral therapy and / or interferon. For example, the combination treatment comprises Navitoclax (ABT-263) and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises A-1551852, For example, the combination treatment comprises A-1331852 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises A-l 155463 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises A-l 155463 dihydrochloride and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises A-1210477 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises Venetoclax (ABT- 199) and one of bothof an antiviral therapy and interferon. For example, the combination treatment comprises ABT-737 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises Sonrotoclax (BGB-11417) and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises S63845 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises S64315 (MIK665) and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises S55746 (BCL201) and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises AZD5991 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises AZD4320 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises BT-1197 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises AMG-176 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises WEHI-539 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises IS21 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises Obatoclax Mesylate (GX15-070) and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises Subatoclax (BI-97C1) and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises Maritoclax (Marinopyrrole A) and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises TW-37 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises UMI-77 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises BDA-366 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises BM-1252 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises BXI-61 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises BXI-72 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises HA14-1 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises BDA366 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises APG-2575 (lisaftoclax) and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises BH3I-1 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises DT2216 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises VU661013and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises a perylene quinone mycotoxin (e.g., Altertoxin I, Altertoxin II, and alterperylenol from Alternaria alternata) and derivatives thereof and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises gossypol and enantiomers thereof and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises AT-101 and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises siRNA and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises Oblimersen and one of both of an antiviral therapy and interferon. For example, the combination treatment comprises tetrocarcin A secreted by Micromonospora sp, and one of both of an antiviral therapy and interferon.
[0260] In some examples, the combination treatment comprises a mechanical intervention, such as a surgical intervention, for example, mechanical or surgical removal of a part of the liver, for example, in conjunction with a partial liver transplant.
[0261] The selective inhibitor of one or more senescence-associated proteins and additional therapeutic agent which make up a combination therapy disclosed herein may be a combined dosage form or in separate dosage forms intended for substantially simultaneous administration. The pharmaceutical agents that make up the combination therapy may also be administered sequentially, with either therapeutic compound being administered by a regimen calling for two-step administration. The two-step administration regimen may call for sequential administration of the active agents or spaced-apart administration of the separate active agents. The time period between the multiple administration steps may range from, a few minutes to several hours, depending upon the properties of each pharmaceutical agent, such as potency, solubility, bioavailability, plasma half-life and kinetic profile of the pharmaceutical agent. Circadian variation of various physiological parameters may also be evaluated to determine the optimal dose interval.
[0262] Kits
[0263] In some embodiments, the present invention provides a kit comprising a selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0264] In some embodiments, provided herein is a kit for treating a Hepadnavirus infection in a subject suffering therefrom, wherein the kit comprises a selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0265] In some embodiments, provided herein is a kit for preventing chronic Hepadnavirus infection in a subject suffering from acute hepadnavirus infection, whereinthe kit comprises a selective inhibitor of one or more senescence-associated BCL-2 family proteins.
[0266] In some embodiments, provided herein is a kit for of monitoring disease progression in a subject with hepadnavirus infection, for example, HBV, wherein the kit comprises one or more reagents for detecting the presence of one or more markers of cell senescence and / or determining a level of senescent hepadnavirus infected cells in a sample taken from a subject.
[0267] In some embodiments, provided herein is a kit for prognosing or determining a likelihood that a subject with chronic hepadnavirus infection, for example, chronic HBV, will respond well to a treatment regime, wherein the kit comprises one or more reagents for detecting the presence of one or more markers of cell senescence and determining a level of senescent hepadnavirus infected cells in a sample taken from a subject.
[0268] Knowledge-Based Systems
[0269] Knowledge-based computer software and hardware for implementing an algorithm to perform a method or a part of a method of the present disclosure. Such computer software and / or hardware are useful for performing a method of the disclosure. Thus, the present disclosure also provides software or hardware programmed to implement an algorithm that processes data obtained by performing the methods of the disclosure via an univariable or multivariable analysis to provide a disease / condition index value and provide or permit a prediction of likelihood of treatment efficacy, likelihood of suffering a disease or condition related to a chronic infection, determination of suitability for a clinical trial, assessment of progression of a disease or condition associated with chronic infection, diagnosis of chronic infection, quantification of cccDNA reservoir cells, and / or monitoring of the efficacy of a treatment in a subject infected with a cccDNA virus.
[0270] In one example, a method of the disclosure may be used in existing knowledgebased architecture or platforms associated with pathology services. For example, results from a method described herein are transmitted via a communications network (e.g. the internet) to a processing system in which an algorithm is stored and used to generate a predicted posterior probability value, which translates to the index of probability of one or more of the aforementioned variables, which is then forwarded to an end user in the form of a predictive report.
[0271] The method of the disclosure may, therefore, be in the form of a kit or computer-based system which comprises the reagents necessary to detect the concentration or levelof cccDNA in cells a biological sample and the computer hardware and / or software to facilitate determination and transmission of reports to a clinician.
[0272] The assay of the present disclosure permits integration into existing or newly developed pathology architecture or platform systems. For example, the present disclosure contemplates a method of allowing a user to determine the status of a subject with respect to chronic cccDNA viral infection and long-term prognosis, the method including: (a) receiving data in the form of levels of cccDNA in a biological test sample relative to a reference level of cccDNA; (b) processing the subject data via univariate and / or multivariate analysis to provide a disease / condition index value; (c) determining the status of the subject in accordance with the results of the disease index value in comparison with predetermined values; and (d) transferring an indication of the status of the subject to the user via the communications network reference to the multivariate analysis includes an algorithm which performs the multivariate analysis function.
[0273] In one example, the method additionally includes: (a) having the user determine the data using a remote end station; and (b) transferring the data from the end station to the base station via the communications network.
[0274] The base station can include first and second processing systems, in which case the method can include: (a) transferring the data to the first processing system; (b) transferring the data to the second processing system; and (c) causing the first processing system to perform the univariate or multivariate analysis function to generate the disease index value.
[0275] The method may also include: (a) transferring the results of the univariate or multivariate analysis function to the first processing system; and (b) causing the first processing system to determine the status of the subject.
[0276] In this case, the method also includes at least one of: (a) transferring the data between the communications network and the first processing system through a first firewall; and (b) transferring the data between the first and the second processing systems through a second firewall.
[0277] The second processing system may be coupled to a database adapted to store predetermined data and / or the univariate or multivariate analysis function, the method include: (a) querying the database to obtain at least selected predetermined data or access to the multivariate analysis function from the database; and (b) comparing the selected predetermined data to the subject data or generating a predicted probability index.
[0278] The second processing system can be coupled to a database, the method including storing the data in the database.The method can also include having the user determine the data using a secure array, the secure array of elements capable of determining quantifying or determining a level of cccDNA and having a number of features each located at respective position(s) on the respective code. In this case, the method typically includes causing the base station to: (a) determine the code from the data; (b) determine a layout indicating the position of each feature on the array; and (c) determine the parameter values in accordance with the determined layout, and the data.
[0279] The method can also include causing the base station to: (a) determine payment information, the payment information representing the provision of payment by the user; and (b) perform the comparison in response to the determination of the payment information.
[0280] The present disclosure also provides a base station for determining the status of a subject with respect to cccDNA virus infection, the base station including: (a)a store method; (b) a processing system, the processing system being adapted to: (i) receive subject data from the user via a communications network; and (ii) determining the status of the subject in accordance with the results of the algorithmic function including the comparison; and (c) output an indication of the status of the subject to the user via the communications network.
[0281] The processing system can be adapted to receive data from a remote end station adapted to determine the data.
[0282] The processing system may include: (a) a first processing system adapted to: (i) receive the data; and (ii) determine the status of the subject in accordance with the results of the univariate or multivariate analysis function including comparing the data; and (b) a second processing system adapted to: (i) receive the data from the processing system; (ii) perform the univariate or multivariate analysis function including the comparison; and (iii) transfer the results to the first processing system.
[0283] The base station typically includes: (a) a first firewall for coupling the first processing system to the communications network; and (b) a second firewall for coupling the first and the second processing systems.
[0284] The processing system can be coupled to a database, the processing system being adapted to store the data in the database.
[0285] The present disclosure is now described further in the following non-limiting examples.
[0286] EXAMPLES
[0287] Example 1: Materials and methods.HBV virus preparation
[0288] HBV viral inoculum was prepared according to previously established technique (Wettengel et al., 2021). HepAD38 cells cultivated until confluency in 5x T150 flasks coated with collagen (by rinsing with 0.02% collagen I (A1048301, Thermofisher Scientific) / dH2O solution for 5 mins). Cells were trypsinised and plated into a 10-layer HYPERflask previously coated in collagen O / N at RT. This was repeated after 4 days with a flipped HYPERflask to colonise the lower surface of the flask. Media was exchanged every 3-4 days and stored at 4°C until purification utilising 2 pooled supernatants.
[0289] Some virus stocks were also produced in Germany by Jochen Wettengel, as previously described (Wing et al. 2019), as well as two reporter HBV (rHBV) stocks: rHB V-TTR-tRFP which expresses turbo RFP (tRFP) controlled by a transthyretin (TTR) promoter and rHBV-TTR-Nano which expresses NanoLuc luciferase under the TTR promoter. These were generated in HepG2 cells with a stable transduction of both a plasmid expressing HBV Polymerase, Surface and X Proteins, as well as a recombinant HBV genome construct encoding HBV pgRNA with the S region replaced by an ORF encoding aforementioned tRFP or Nanoluc luciferase under the TTR promoter.
[0290] Purification and concentration of HBV via Heparin Affinity Chromatography
[0291] Ice cold HBV supernatant was filtered through a 0.45pm Bottle Top Filter (295-4545, Thermofisher Scientific) under vacuum pressure. Using a peristaltic pump (GFAM00051, Gibson, Middleton, WI, USA), supernatant was filtered through HiTrap Heparin HP columns (17040703, Cytiva Wilmington, DE, USA) in parallel at a flow rate of 10 mL / min per column. Columns were then joined in series and eluted into 17 mL of 4x PBS at 2 mL / min. Eluate was concentrated Using Amicon Ultra-15 centrifugal filters lOOKDa (C7715, Merck, Darmstadt, Germany) in 30 min spins at 4000g until concentrated to approximately l-2mL. Viral inoculum was stabilised with FBS at a ratio of 1 : 1 and then stored at -80°C.
[0292] In vitro infection model
[0293] HepG2-NTCP, PLC / PRF / 5 and Hep3B cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (11965092, Thermofisher Scientific, Waltham, MA, USA) supplemented with 10% Foetal Bovine Serum (12003C, Sigma Aldrich, St Louis MO, USA) and 2mM L-glutamine (growth media). AD38 cells were maintained in F12 / DMEM supplemented with 10% Foetal Bovine Serum and 2mM L-glutamine.Cells were maintained at 37°C and 5% CO2 in a cell incubator (BD053, Binder, Bohemia, NY, USA).
[0294] HepG2-NTCP cells were seeded at 5x105 cells / mL and infected with HBV-WT (#), HBV-Luc (#) or HBV-Nano (#) at up to 500 VGE / cell in 250pL of culture media supplemented with 4% v / v polyethelene glycol 8000 (Sigma Aldrich, St. Louis, MO USA) and 2.5% v / v DMSO. Cells at confluency was maintained in growth media with 2.5% v / v DMSO. Cells were washed twice 24 hours post-infection with lx phosphate-buffered saline (PBS). Media was changed every 3 days.
[0295] In vitro senolytic drug treatment
[0296] Senolytic compounds used in experiments are listed in Table 1. Compounds were all sourced from Selleckchem (Houston, TX USA). HepG2-NTCP cells infected with HBV-WT or HBV-Nano.
[0297] Table 1: List of senolytic compounds used in drug discovery assays Compound Name Catalogue
[0298] Number
[0299] BPTES S7753
[0300] Telaglenastat (CB-839) S7655
[0301] ABT-737 SI 002
[0302] Navitoclax (ABT-263) S1001
[0303] Alvespimycin (17-DMAG) HC1 S1142
[0304] Dasatinib S1021
[0305] Quercetin S2391
[0306] Gambogic Acid S2448
[0307] Sabutoclax S8061
[0308] A-1331852 S7801
[0309] Gossypol S6852
[0310] Venetoclax (ABT-199) S8048
[0311]
[0312] Obatoclax Mesylate (GX15-070) S1057
[0313] X-ray Irradiation
[0314] HepG2-NTCP cells were plated in a 24 or 96 well plate and were irradiated with 10 Gy using an x-ray irradiator. Cells were incubated post-treatment for 10 days for generation of senescent cells.CCK8
[0315] Toxicity of senolytic compounds was determined with calculation of their CC50, as calculated by Cell Counting Kit 8 (CCK8) (ab228554, Abeam, Cambridge, UK). Cells were plated in a 96 well plate at 10000 cells / well. 24 hours later cells were treated with a serial dilution of senolytic drugs for 18h. lOul of CCK8 solution was added per well and incubated at 37c, 5% CO2 for 2 hours in darkness. Plate absorbance was read at 460nm on a Spectramax Id5 (Molecular devices, San Jose, CA, USA)
[0316] Nanoluc luciferase assay
[0317] HepG2-NTCP cells were infected with HBV-Nano using standard infection protocol. Cell supernatant was taken every 3 days and stored at -20°c until end of collection. Nano-Gio® Luciferase Assay System (N1120, Promega, Madison WI, USA) was used to quantify nanoluc expression as a measure of cccDNA activity. Assay was prepared as per manufacturer protocol. 20 pL of supernatant was diluted with dH2O up to lOOpl in a 96 well plate. Nanoluc reagent was prepared fresh by mixing Nano-Gio Substrate with Buffer at a 1:50 ratio. lOOpl of Nanoluc reagent was added per well and incubated for 3 mins RT. Luminescence was measured on a SpectraMax Id5 multiplate reader (Molecular devices).
[0318] Table 2: Primary antibodies used
[0319] Primary antibody Catalogue Number Supplier
[0320] Anti-HBcAg Discontinued Dako
[0321] Anti -p 53 ab26 Abeam
[0322] Anti-p21 abl09199 Abeam
[0323] Anti-GFP Al 1122 Invitrogen
[0324]
[0325] Anti-CDKN2A / p 16INK4a ab211542 Abeam
[0326] FACS
[0327] HepG2-NTCP cells infected with rHBV-TTR-RFP, were trypsinised and resuspended in PBS with 0.5% FBS v / v and sorted using a BD Influx cell sorter (BD Biosciences, Franklin Lakes, NJ USA), gating for size, granularity, and RFP positivity. Downstream cells were either seeded into 96 well plates for live cell imaging or processed for downstream RNAseq.
[0328] Live cell imagingFACS sorted cells were plated at approximately 2000 cells / well in a 96 well format lined with 0.02% collagen I and treated with 1:1 ratio of fresh media and conditioned media from HepG2-NTCP cells cultured for 3 days. Cells were observed with a JuliBR live cell imaging machine (NanoEntek, South Korea). Length of assay was 48 hours, with a picture taken every 15 minutes.
[0329] RNAseq
[0330] Total RNA was purified from FACS sorted HepG2-NTCP cells using a MagMAX™-96 Total RNA Isolation Kit (AMI 830, Invitrogen, Waltham MA USA) following the kit instructions. RNA was eluted into 20pL Elution Buffer and initial RNA quantity and quality was determined using a Tapestation 4200 (Agilent Technologies, Santa Clara CA USA). cDNA was generated and amplified using a NEBNext® Single Cell / Low Input RNA Library Prep Kit for Illumina® (E6420S, New England Biolabs, Notting Hill, VIC, Australia) in conjunction with NEBNext® Multiplex Oligos for Illumina® (Index Primers Set 1) (E7335S, New England Biolabs) according to manufacturer instructions. Concentration of RNA-seq libraries was confirmed using Qubit (Invitrogen).
[0331] cDNA was processed at the Australian Genome Research Facility, and data was analysed using Bioconductor using the edgeR package (version number).
[0332] Quantification using Ilastik machine learning software
[0333] Immunofluorescent in vitro and in vivo images were edited using Oly VIA image viewer software (Olympus, Version 3.3) or FIJI (https: / / imagej.net / software / fiji / , Version 2.15.1) and analysed using Fiji manual counting, segmentation and Ilastik classification, segmentation and analysis software (https: / / www.ilastik.org / , Version 1.3.3).
[0334] For manual counting of cells, cells were individually marked using the FIJI counting tool and recorded in Microsoft Excel. For segmentation, images were converted to 8-bit and a threshold was set for classification of pixels as either cell or background. Overlapping and clumped cells were minimised via use of the watershed tool to separate connected components. Particles were analysed with minimum area of 100 pixels and number of cells recorded.
[0335] Using Ilastik, images were taught using user specified training data using brush stroke labelling as to what pixels are background and which are cell. This training data was extrapolated to the whole data set of immunofluorescent images from the same experiment, and each individual pixel was assigned a predicted classification ofbackground or cell. This data was then used in addition to object-level characteristics such as shape in order to generate data on predicted objects.
[0336] DNA extraction
[0337] DNA from in vitro HepG2-NTCP cells was extracted using DNeasy Blood and Tissue Kit (69581, Qiagen, Hilden, Germany) following manufacturer protocol. Extracted DNA was eluted in 50pL of elution buffer prewarmed to 37°C.
[0338] To extract HBV viral nucleic acid, a High Pure Viral Nucleic Acid Kit was used following manufacturer protocol (11858874001, Roche, Basel, Switzerland). Extracted DNA was eluted in 50pL of elution buffer prewarmed to 37°C.
[0339] Purity and concentration of DNA extracts were quantified using a NanoDrop 2000 Spectrophotometer (ThermoFischer Scientific, Wilmington, DE, USA). IpL of DNA extract was placed on measurement pedestal and absorbance readings were calculated. This is quantified using a modified Beer-Lambert equation:
[0340] c = (A * e) / b
[0341] Where c is the nucleic acid concentration in ng / uL, A is the absorbance in AU, 8 is the wavelength-dependent extinction coefficient in ng-cm / pL and b is the pathlength in cm. For DNA, 8 = 50ng-cm / uL.
[0342] CinqPCR
[0343] CinqPCR was performed as described in Example 2. In brief, extracted DNA prepared in either a 96 well PCR plate or 8-well PCR strips depending on number of samples. Digestion reaction consisted of approximately 1400ng of DNA, lx Cutsmart buffer, 7.5U RecJf, 10U Hhal made up to a total volume of 20pL in dH2O, incubated in a MiniAmp thermocycler (A37834, ThermoFisher Scientific) for 4 cycles of 15min at 37°C, and 15 min at 42°C and followed by heat-inactivation at 80°C for 20 minutes. lOpL of circularising reaction was added to samples, consisting of lx Cutsmart Buffer, 500U T4 DNA Ligase, 3mMol molecular-grade ATP in dH2O. This was incubated in a thermocycler at 16°C for 2hr, followed by heat inactivation for 20min at 8°0C. 5pL linearisation reaction was added consisting of lx Cutsmart buffer, 10U Xbal in dH2O. This was incubated in a thermocycler at 37°C for Ih and inactivated at 80°C for 20 minutes. Digested DNA was stored at 4°C until required.
[0344] Primers used for ddPCR were previously designed (Tu et al., 2020) and synthesised by Integrated DNA Technologies (Coralville, Iowa, USA) (Table 3).
[0345] Samples were diluted 2.5-fold, and ddPCR reaction mix was prepared as follows for 22pL per reaction: llpL of 2x ddPCR Supermix for probes (1863010, Bio-rad,California USA), 1.1 pL of TaqManTM Copy Number Reference Assay (4403316, ThermoFisher Scientific), 0.033pL of 100 pM forward primer (cccDNA, total HBV or HBx), 0.033 pL of lOOpM reverse primer (cccDNA, total HBV or HBx), 0.033 pL of lOOpM probe (cccDNA, total HBV or HBx), 5.5pL of diluted sample, and 4.5pL of dH2O. cccDNA primers are listed in Table 4.
[0346] ddPCR droplets were generated on a QX200 droplet generator (1864002, Biorad). 20pL of ddPCR mix was added to the sample wells of the DG8 droplet generator cartridge (1864008, Bio-rad) which is mounted in a DG8 Cartridge holder (1863051, Bio-rad), 70pL of droplet generation oil for probes (1863005, Bio-rad) was added to oil wells. DG8 Gasket (1863009, Bio-rad) was attached to the cartridge holder and cartridge was placed in the droplet generator. 40pL of generated droplets were slowly pipetted (>5 seconds draw and plunge) into a ddPCR 96-well plate (12001925, Bio-rad). When all samples were loaded the plate was sealed with aluminium foil sealing (1814040, Biorad) using a PX1 PCR Plate Sealer (1814000, Bio-rad). Samples were run in a MiniAmp thermocycler with the following program: 10 min at 95°C; 40 cycles of 10 s at 95 °C, 15 s at 54°C, and 20 s at 68°C; 10 min at 95°C, and hold at 12°C. Ramp rate was set to 2°C / s.
[0347] Plate was transferred to a QX200 Droplet Reader (1864003, Bio-rad) and read using ddPCR Droplet Reader Oil (1863004, Bio-rad). Template was setup using Quantasoft software using channels for FAM and VIC. Data was analysed using Quantasoft and manual thresholds for positive and negative values were assigned based on positive and negative controls. HBV DNA (cccDNA, total HBV DNA, HBx) was normalised to RNAseP, which is present at two copies per cell.
[0348] Table 3: Primers used in ddPCR assays
[0349] Primer Name Sequence SEQ ID NO: cccDNA cinqPCR CACTCTATGGAAGGCGGGTA 7
[0350] Forward primer
[0351] cccDNA cinqPCR ATAAGGGTCGATGTCCATGC 8
[0352] Reverse primer
[0353] cccDNA cinqPCR FAM- AACACATAGCGCACCAGCA- 9
[0354] Probe BHQ1
[0355] Total HBV cinqPCR GTGTCTGCGGCGTTTTATCA 10 Forward primer
[0356] Total HBV cinqPCR GACAAACGGGCAACATACCTT 11
[0357]
[0358] Reverse primerTotal HBV cinqPCR FAM-TGAGGCATAGCAGCAGGATG- 12
[0359] Probe BHQ1
[0360] HBx cinqPCR CTKCGCGGGACGTCCTTT 13 Forward primer
[0361] HBx cinqPCR AGTCCAAGAGTCCTCTTATG 14 Forward primer
[0362] HBx cinqPCR Probe FAM-TTCGCTTCACCTCTGCACG- 15
[0363]
[0364] BHQ1
[0365] Table 4: HBV cccDNA qPCR primers
[0366] Primer Name Sequence SEQ ID NO: cccDNA qPCR CCGTGTGCACTTCGCTTCA 16 Forward primer
[0367] cccDNA qPCR GCACAGCTTGGAGGCTTGA 17 Reverse primer
[0368] cccDNA qPCR Probe FAM- 18
[0369] CATGGAGACCACCGTGAACGCCC-
[0370]
[0371] BHQ1
[0372] *FAM and BHQ1 are fluorophore tags used for the taqman-based PCR assay.
[0373] ELISA ELIS As for HBV HBsAg, HBV HBeAg and Human Albumin were performed with AiD HBsAg ELISA kit (Wantai, Beijing, China), AiD HBeAg ELISA kit (Wantai, Beijing, China), and Human Albumin ELISA Kit respectively (EHALB, Invitrogen). ELISA protocol for all three are standardised to the following:
[0374] A serial dilution of patient sera was used for generation of the standard curve. Samples were analysed in duplicate to ensure reliability. lOOpL of wash solution was soaked per well for 5 mins and pat dry on a paper towel. 20 pL of specimen diluent was pipetted per well. lOOpL of sample was added to each well, mixed, and incubated at RT in the dark for 60 mins. Wells were washed 3x with lOOpL wash solution each for 30-60s and pat dry on paper towels between washes. 50pL of HRP -conjugate was added to each well, covered and incubated for 30 mins RT. Wells were washed 5x with lOOpL wash solution for 30-60s and pat dry as previous. 50pL of chromagen solution A and chromagen solution B were added to each well, covered and incubated for 15 mins RT in the dark. Reaction was stopped with 50pL of stop solution and tapped gently to mix. Absorbance at 450nm and 630nm was read on a Spectramax Id5 microplate reader(Molecular devices) within 30 minutes. Readings were recorded in SoftMax Pro (version 7.2) and exported as CSV.
[0375] In vivo models — Mouse strains
[0376] Male Balb / c and C3H / HeN mice, aged 6-8 weeks were obtained from Animal Resources Centre (Perth, WA, Australia) and their successor OzGene (Perth, WA, Australia). Mice were housed in a pathogen-free environment with a 12-hour light / dark cycle and room temperature set to 22°C. Cages were lined with fine sawdust and changed weekly. Mice were provided with standard rodent chow and water ad libitum.
[0377] In Vivo Transduction
[0378] Balb / c and C3H / HeN (Animal Resources Centre / Ozgene) were transduced with a GFP AAV8 construct (Synthesised by VGEF, Sydney, NSW, Australia) at 2 concentrations calculated to produce expression of GFP in 30% and 50% of hepatocytes (3xl010and 5xl010vg / mouse). GFP was used as a model for mock HBV, as it is similarly lost during mitosis.
[0379] In vivo generation of reservoir cells
[0380] Mice were injected twice weekly with 0.6mL / kg body weight of CC14 (Accustandard, New Haven, CT, USA) in com oil (Sigma Aldrich) or a vehicle control to induce liver turnover for a duration of 1, 2, 3 weeks. Mice were either harvested or this was followed by daily injections of 1.5mg / kg Navitoclax (SI 001, Selleckchem) for 2 weeks with an interim 1 week rest period midway. Livers were collected at 6 weeks post-transduction.
[0381] Livers were sectioned on a CryoStar NX70 cryostat (Thermo Fischer Scientific, Waltham, MA USA) and fixed with 300pL 4% w / v formalin for 5 minutes at room temperature. Sections were permeabilised with 0.25% v / v Triton-X in IxPBS for 20 minutes at room temperature. GFP was detected with 300pL of a 1 :500 dilution of Anti-GFP Antibody (A-11122, Invitrogen) in 2% BSA / PBS overnight at 4°C. Slides were washed with 3xPBS and incubated with 1:1000 AF545-conjugated goat anti-rabbit secondary antibody (A-11010, Invitrogen) and Ipg / mL Hoechst 33342 (H1399, Invitrogen) in ImL 2% BSA / PBS in the dark for 30 minutes. Slides were washed with 3xPBS and mounted with 40% glycerol / TBS. Images of the whole liver section were taken with a VS 120 Virtual Slide microscope (Olympus, Shinjuku-ku Tokyo Japan) at 20x magnification using FITC, Tx-Red and DAKO filters.Tissue fixation
[0382] Formalin Fixed paraffin embedded tissue
[0383] Harvested mouse liver tissue was sectioned into pieces of ~5 mm thickness, and placed in plastic cassettes (#) to snap freeze in liquid nitrogen. Tissue was fixed in 4% v / v formalin on a shaker at room temperature (RT) overnight (O / N) and washed with 70% v / v ethanol. Fixed tissue was embedded in paraffin wax blocks and sectioned at 5 pm. Embedding and sectioning was carried out on a microtome (RM2125RT, Leica, Wetzlar, Germany), by Westmead Scientific Platforms on Superfrost Plus microscope slides (#).
[0384] Dewaxing
[0385] Slides were dewaxed by 3x xylene baths for 2x 3 minutes each, and then rehydrated through a series of graded ethanol baths as follows: 100% ethanol for 2x 3 minutes, 100% ethanol for 2x 3 mins, 90% for 2x 3 minutes, 90% for 2x 3 minutes, 70% for lx 1 minute, dH2O for lx 1 minute and PBS for lx 1 minute.
[0386] Anti en Retrieval
[0387] F or antigen retrieval, a Coplin j ar with 200mL of 1 OmM sodium citrate buffer (pH 6.0) was set inside a beaker of water and preheated in a microwave on the highest setting for 5 minutes. Slides were added to the sodium citrate buffer and heated at half-power for 8 minutes. Slides were transferred to ice-cold PBST and cooled for 20 minutes. Samples were then treated for immunofluorescence as per protocol.
[0388] OCT tissue sections
[0389] Harvested mouse liver tissue was sectioned into pieces of ~2mm thickness and placed into Tissue-Tek Standard Cryomold® 25 x 20 x 5mm moulds (Sakura Finetek, Torrance, CA, USA) and embedded in OCT compound (4583, Sakura Finetek) and frozen on dry ice. Once fully frozen, samples were stored at -80°C. Tissue was sectioned on a Cryostar Nx70 (Epredia, Kalamazoo, MI, USA) by Westmead Scientific Platforms.
[0390] Immunofluorescence
[0391] HepG2-NTCP cells were plated on glass cover slips and infected as per infection protocol. Following infection, cells were fixed with 4% paraformaldehyde for 20 minutes and washed 4x with PBS. Cells were permeabilised with 0.4% Triton-x / PBS for 15 minutes and washed 3x PBS. Primary antibody treatment was overnight at 4°C or 2 hours at RT using the following: 1 : 1000 Anti-HBcAg (Dako), 1 : 1000 Anti-p53 (ab26, Abeam),1:1000 Anti-p21 (ab 109199, Abeam), Anti-CDKN2A / pl6INK4a (ab211542, Abeam). All primary antibodies (Table 2) were made up in 2% BSA / PBS. Primary antibodies were retrieved and used up to 3 times. Cells were washed with 3x PBS and secondary antibodies in 2% BSA / PBS and 1:1000 Hoechst were added for 30 minutes. Secondary antibodies used were: 1:1000 Anti-Rabbit AF488 (#), 1:1000 Anti-Rabbit AF549 (#), 1:1000 Anti-mouse AF488 (#), 1:1000 Anti -mouse AP549 (#), and 1:1000 Hoechst (Invitrogen). Cells were washed 3x PBS and mounted onto Superfrost Plus microscope slides (Epredia, Kalamazoo Mi, USA) with Prolong Gold antifade mountant (Pl 0144, ThermoFisher Scientific).
[0392] Mounted tissue sections and in vitro cells were imaged on either a BX53 light / fluorescent microscope (Olympus, Tokyo, Japan), VS 120 Slide Scanner (Olympus) or VS200 Slide Scanner (Olympus).
[0393] B-galactosidase
[0394] For in vitro fluorescent detection of b-galactosidase activity was detected using CellEvent Senescence Green Detection Kit (ThermoFisher Scientific) according to manufacturer protocol. Cells were stained after with 1 : 1000 Hoechst.
[0395] Immunohistostaining of in vivo sections was achieved via Senescence P-Galactosidase Staining Kit (9860S, Cell Signalling Technology, MA, USA), and method was followed according to the manufacturer protocol. In brief, OCT was removed via 3x washes with lx PBS, and a hydrophobic barrier drawn to contain samples with a wax pen (Z672548, Merck). Cells were fixed with lx Fixative Solution for 15 minutes, and rinsed with 2x washes with lx PBS. Samples were incubated O / N in a dry incubator at 37°C in 250pL P-Galactosidase Staining Solution. Solution was removed without washing and coverslips mounted with 70% glycerol / PBS.
[0396] Lipofuscin Staining
[0397] Lipofuscin staining was achieved via staining with Sudan Black B (SBB) according to previously established technique (Evangelou et al., 2017). In short, 0.7g SBB powder (W000524, Sigma- Al dritch) was dissolved in lOOmL 70% EtOH O / N in a media bottle stirred continuously at 500RPM with a stir bar. Solution was filtered first through filter paper and then through a fritted glass filter under suction. OCT sections were washed 3x PBS to remove OCT, then fixed for 15 minutes in 4% PF A. SBB was deposited on a cover slip via syringe with a 25 pm syringe filter and slide with section was inverted onto the cover slip. Reaction was observed for ~5 minutes, then coverslipwas removed, and slide was washed in 3x 50% EtOH and washed with dH2O. Slides were mounted in 40% glycerol / TBS.
[0398] Example 2: Pan-genotype cccDNA inversion and quantification PCR (pan-cinqPCR)
[0399] Total DNA extracts were digested in a 20 gL restriction digestion reaction containing 200ng purified plasmid carrier DNA (for example, pWPI-GFP), lx NEB 1.1 restriction enzyme buffer (B7201, New England Biolabs, Ipswich, MA USA), 2.5U RNaseH (M0297, NEB), 10 U Thermolabile Exonuclease I (M0568, NEB) and 2.5U of Sau3 Al (R0169, NEB). The digestion reaction was incubated for 60min at 37°C followed by heat-inactivation of the enzymes at 70°C for 20 min.
[0400] To circularise the digested fragments, a lOgL solution containing 500 U of T4 DNA Ligase (M0202, NEB) in lx 1.1 restriction enzyme buffer and 3 mMol molecular-grade ATP (P0756, NEB) was added to the reaction. The reaction was incubated at 16°C for 2 hr, followed by an inactivation step of 65°C for 20 min. A final linearization step was performed by adding 5 gL solution containing 5U ApaLI (R0507, NEB) in lx 1.1 restriction enzyme buffer and incubating at 37°C for 15 min, and then storing at 4°C until further use.
[0401] For digital droplet (dd)PCR analysis, 5 gL of the inverted product was put in a 20 pL ddPCR reaction composed of lx ddPCR Multiplex Supermix for Probes (12005909, Biorad, Hercules, CA USA), lx VIC-labelled TaqMan™ Copy Number Reference Assay for the human RNase P gene (a standard and widely-used reference standard, 4403328, Applied Biosystems, Foster City, CA USA), 225 pmol of HBV cccDNA-specific primers and probe, The forward primer, reverse primer and probe sequences to quantify the inverted HBV cccDNA fragment were 5’-TTCGCTTCACCTCTGCACG-3’ (SEQ ID NO: 1), 5'-AAAGGACGTCCCGCGCAG-3' (SEQ ID NO: 2), and 5'-FAM-TCAAGCCTCCAAGCTGTGC-BHQ1-3' (SEQ ID NO: 3), respectively.
[0402] For the same samples, total HBV DNA copies was quantified using the same concentration of alternate primers. The forward primer, reverse primer and probe sequences to quantify total HBV DNA were 5'-GTGTCTGCGGCGTTTTATCA-3' (SEQ ID NO: 4), 5'- GACAAACGGGCAACATACCTT-3' (SEQ ID NO: 5), and 5'-FAM-TGAGGCATAGCAGCAGGATG-BHQ1-3' (SEQ ID NO: 6), respectively. Droplets were generated according to the manufacturer’s protocol using a QX200 Droplet Generator (Biorad). Intra-droplet PCR was carried out using the following protocol: an initial lOmin denaturation, enzyme activation and droplet stabilisation step at 95°C; followed by 40 cycles of a 10s denaturation step at 95°C, a 15s annealing stepat 54°C and a 60s elongation step at 68°C, finished with a 10 minute enzyme deactivation step at 95 °C. Products were then stored at 12°C until droplet reading using a QX200 Droplet Reader (Biorad), quantification using FAM and VIC channels, and data analysis using QuantaSoft Analysis Pro (Biorad).
[0403] A cinqPCR assay that could only detect the cccDNA of the lab HBV strain (lab-cinqPCR) has been tested against competing cccDNA detection methods with labcinqPCR showing similar or better sensitivity and specificity. These results have been published (Tu et al., 2020).
[0404] In these studies, pan-cinqPCR could readily distinguish between cccDNA (in vitro- QnQ at S) and HBV replicative forms (DNA extracted from purified virus stock). DNA extracts from uninfected cells spiked with either artificial cccDNA (-100% total HBV DNA detected as cccDNA) or virion-derived HBV DNA (<1 / 1000 total DNA copies detected as cccDNA) resulted in similar discrimination to lab-cinqPCR. Analysis of total DNA extracts from HBV infected cells also resulted in identical levels of cccDNA quantification.
[0405] Intrahepatic cccDNA levels in resection tissue from HBeAg -negative patients infected with Genotype B and C HBV were detected (previously difficult to analyse due to low cccDNA levels). Lower levels of cccDNA in patients with spontaneous HBsAg-loss compared to HBsAg-positive patients were demonstrated. This defines an aspirational threshold for functional cure.
[0406] The standard approach to detecting and quantifying cccDNA has used a variety of endonucleases (e.g. T5 exonuclease, Exo I and Exo III, plasmid-safe DNase, or Exo V) to digest all DNA that is not covalently closed prior to PCR with HBV-specific primers. The data presented here shows that the novel pan-cinqPCR assay is equivalent or better to these previous methods with respect to accuracy, sensitivity, and precision (Figure 4).
[0407] Sensitivity: pan-cinqPCR can detect less than 10 copies of cccDNA per ddPCR reaction, and so is >100000 times more sensitive than a standard Southern blot hybridisation assay (with a lower limit of detection of -100000-1000000 copies of HBV cccDNA). Enzymatic digestion of HBV DNA replicative intermediates (e.g. with exonuclease V, plasmid-safe DNase, T5 exonuclease, or a combination of Exonucleases I and III) paired with PCR also provides high sensitivity. However, exonuclease-based methods require hundreds of nanograms of total DNA, whereas pan-cinqPCR can be conducted even on ten nanograms without alteration to the method. Further, exonuclease treatments may lead to: (1) over-digestion and destruction nicked cccDNA; and (2) under-digestion and preservation of amplifiable HBV DNA replicative intermediates.Precision: Cellular DNA is maintained in an amplifiable form during the pan-cinqPCR assay, and not completely hydrolysed to individual nucleosides as with exonuclease digestion. Thus pan-cinqPCR allows normalisation to a cellular gene (in this case, RNaseP) using a duplexed PCR assay and so measures cccDNA per cell with high accuracy (particularly when paired with high precision ddPCR).
[0408] Clinical application: The previously described related assay lab-cinqPCR will only detect the lab strain of HBV. The assay described here can be used for all known sequences of HBV DNA and so does not need to be changed for each patient strain.
[0409] Accordingly, pan-cinqPCR:
[0410] 1) Allows longitudinal sampling of the liver cccDNA levels in HBV patients through a minimally-invasive fine needle aspirate biopsy.
[0411] 2) Determines if anti-HBV therapies efficacy in reducing intrahepatic cccDNA (e.g. in pre-clinical trials of investigational drugs or during clinical management of chronic HBV patients).
[0412] 3) Acts as a clinical biomarker: e.g. predicting if it is safe for a patient to discontinue long-term nucleotide / nucleoside analogue therapy and if they will maintain virological control; or quantifying the risk of viral reactivation in a person who has undergone HBsAg-seroconversion (e.g. prior to treatments that lead to immunocompromisation, such as chemotherapy).
[0413] 4) May be provided as a service
[0414] 5) can be developed as a commercial kit.
[0415] All the described advantages and properties make this the only assay that can detect cccDNA in a small sample acquired by a minimally-invasive fine needle aspirate biopsy.
[0416] Example 3: Discovery of reservoir cells
[0417] The present inventors have found evidence for a previously undefined cell type that is responsible for hepatitis B virus persistence.
[0418] Without being bound by theory, it is hypothesised that senescent infected cells maintain viral infection by not undergoing mitosis and evading the antiviral immune response (Figure 1).
[0419] In previous work, cccDNA levels after mitosis were modelled and it was found that the majority of cccDNA is lost with mitosis. However, a rare cell population maintains cccDNA (-1 / 500 cells, Figure 2A) by not undergoing mitosis. The persistently infected cells displayed at least 2 markers for senescence: p21 expression and intrinsic P-galactosidase activity (Figure 2B). Cells were isolated maintaining cccDNA by using a recombinant HBV encoding RFP and live cell-sorting (Figure 2C, virus developed byProf Ulrike Protzer and Dr Jochen Wettengel, Munich). Cell transcriptome was anlaysed using low-input RNAseq, and found that persistently infected cells upregulate senescence-associated pathways, including peptidase activity and triglyceride metabolism
[0420] Following on from the discovery above that HBV cccDNA is lost during hepatocyte mitosis, the present inventors have now identified a unique sub -population of “hibernating” liver cells that maintains the HBV virus, i.e. do not undergo mitosis. cccDNA kinetics after mitosis was measured using a high-precision assay developed by the present inventors and described above at Example 2. Mitosis of HBV-infected cells was induced. With limited mitosis, the decrease in cccDNA levels matched mathematical models where cccDNA is lost with mitosis. However, after continued mitosis, cccDNA levels were 100-fold higher compared to the loss model, suggesting that cccDNA is maintained in a specific rare cell subset (accounting for 1 out of -500 cells). Immunofluorescences was performed and these cells and showed that these cells demonstrated markers of mitotic arrest (p21 expression and show P-galactosidase activity). The transcriptomic profile of these cells has also been isolated and analysed, finding upregulation of metabolic pathways associated with senescence. Accordingly, the present inventors have identified two dynamics are at play: 1) cccDNA is lost in cells that divide; and 2) cccDNA persists in rare hibernating “reservoir” cells that do not divide. Without being bound by theory is it likely that the livers of patients on long-term antiviral therapy undergo similar dynamics. Over time, the liver turns over and cccDNA levels decrease in the absence of new infections. However, reservoir cells persist, which has also been observed in in vivo models of HBV infection. Accordingly, reservoir cells must be eliminated to achieve HBV cure.
[0421] Example 4: Therapeutic elimination of reservoir cells.
[0422] Senescent cells undergo mitotic arrest. To test the hypothesis that senescent cells represent the reservoir cells. To test this hypothesis, a small panel of senolytics (drugs that induce apoptosis of senescent cells) were screened for their effect on the number of HBV reservoir cells. It was found that persistent infected cells can be eliminated with senolytic therapy. The number of senescent infected cells could be reduced using a single 24h treatment with senolytics (Figure 3 A and 3B). 800nM Navitoclax (a Phase 2 / 3 orally available senolytic used in blood cancer therapy that specifically induces apoptosis of senescent cells) induced a ~4-fold reduction in senescent infected cells. Moreover, IpM of A-1331852 (a pre-clinical first-in-class, orally available BCL-XL inhibitor) induced a 12-fold reduction in senescent infected cells. No toxicity was observed in non-infectedcells for either compound at these doses, by cell morphology or a CCK8 viability assay. Exactly as hypothesised, two compounds (Navitoclax and A-1331852) reduced reservoir cells in vitro by ~4-fold and 12-fold respectively. Senescent reservoir cells can be eliminated in vitro and in vivo by Navitoclax or A-1331852, two orally-available drugs that kill senescent cells.
[0423] The same process was followed using WEHI-539, A-133852, A-l 155463, and A-1155463 dihydrochloride, with similar results (see FIGs 6 and 7). Notably, A-l 155463 dihydrochloride, an oral formulation, reduced cccDNA down to undetectable (hollow data points represent LLoD of the assay in FIG 6).
[0424] To test the therapeutic approach in vivo, a novel mouse model of viral persistence was developed. The livers of mice were transduced with an adeno-associated virus (AAV) construct expressing GFP, which forms an episomal genome like cccDNA. Liver damage was induced using a standard dose of carbon tetrachloride, resulting in liver turnover. This led to a significant loss of GFP-expressing cells (as expected). The surviving GFP-expressing cells were designated as senescent “infected” cells. Administration of 1.5mg / kg / day Navitoclax (IP injection) for 14 days reduced senescent “infected” cell counts by 3 to 4-fold compared to controls (Figure 3C), consistent with the in vitro data. Moreover, it was demonstrated that a daily 1 ,5mg / kg dose of Navitoclax for 14 days could reduce reservoir cells in vivo by ~4-fold in a mouse model of HBV reservoir cells. This represents a completely novel approach to treating, preventing, and ultimately curing hepatitis B infection.
[0425] Example 5: In vitro characterisation and elimination of HBV reservoir cells HBV chronic infection is characterised by persistence of cccDNA within hepatocytes. In order to understand the mechanisms by which this occurs, and potential methods which could be used to eliminate viral reservoirs. Previous studies into the fate of cccDNA after mitosis of HBV infected cells have found mixed results. In some experimental models cccDNA is entirely lost while others have indicated full or partial survival of cccDNA in daughter cells. There may therefore be a sub-population of cccDNA-retaining hepatocytes which resist mitosis. Accordingly, these host cells were characterised within the context of mitotic arrest and potential avenues of eradication were analysed.
[0426] Senescent cells: a possible mechanism of cccDNA retention
[0427] Cellular senescence describes the state of permanent mitotic arrest at which point cells reach their replicative limit. These cells may have DNA damage or be subject tocellular stress, becoming unable to replicate yet remaining metabolically active. Phenotypically, senescent cells are known to exhibit altered morphology and structure, which varies by cell type but often include changes to the nuclei including enlargement, multinucleation and irregular shape.
[0428] Commonly, these cells then begin producing senescence-associated secretory phenotype (S ASP) factors, a variety of pro-inflammatory cytokines, chemokines, growth factors, and proteases which alter the surrounding tissue microenvironment.
[0429] As the defining feature of senescent cells is their inability to undergo mitosis, this represents a potential subpopulation of hepatocytes which were tested for their potential harboring of HBV cccDNA. Moreover, expression of a SASP may induce immune evasion via pathways such as HLA-E mediated NK and CD8+ cells inhibition, preventing viral clearance.
[0430] Cellular senescence may be triggered by multiple causes such as DNA damage, oxidative stress and telomere shortening. While it is known that hepatocytes in a healthy liver have preserved telomere length, telomere attrition may be associated with inflammatory signalling such as those experienced during HBV immune clearance. Tachtatzis et al., (2015) found HBV infected patients had reduced number and length of hepatic telomeres, as well as an association with hepatocyte cell cycle arrest at G1 mediated by p21. While hepatocyte cyclin DI expression (a marker for G1 phase entry) was not significantly different between chronic HBV infection and control, all other tested markers of cell cycle phase were decreased in chronic HBV infection. Including MCM-2 (cell cycle entry), cyclin A (S phase), cyclin B 1 (G2 phase) and PH3 (transition from G2 through mitosis).
[0431] Senolytics
[0432] Senolytic therapy is well studied in cancer research, considering that growth arrest is recognised as a central aspect of tumour biology and survival mechanism in response to anti-cancer therapies. Senolytics are currently not used as an anti-HBV agent. Senolytic therapy was tested after several rounds of liver turnover in order to remove reservoir cells.
[0433] Table 5: Senolytic compounds tested and their targets
[0434] Compound Name Target
[0435] BPTES Glutaminase GLS1 (KGA) inhibition Telaglenastat Glutaminase inhibition
[0436]
[0437] ABT-737 Bcl-2 family inhibitionNavitoclax Bcl-2 family inhibition
[0438] WEHI-539 Bcl-2 family inhibition
[0439] A-l 155463 Bcl-2 family inhibition
[0440] A-l 155463 dihydrochloride Bcl-2 family inhibition
[0441] Alvespimycin HSP90 inhibition
[0442] Dasatinib + Quercetin Abl, Src, c-Kit inhibition
[0443] Gambogic Acid SUCH activatino PI3K inhibition
[0444] Sabutoclax Bcl-2 family, Mcl-1 Bfl-1 , Caspase inhibition A-1331852 Bcl-2 family inhibition
[0445] Gossypol Bcl-XL inhibition
[0446] Venetoclax Bcl-2 family, 5a-reductase 1, 3a- hydroxysteroid dehydrogenase inhibition Obatoclax Bcl-2 inhibition
[0447]
[0448] BPTES Bcl-2 family inhibition
[0449] cccDNA is lost in mitosis, however is retained in post-mitotic cells
[0450] The dynamics of HBV cccDNA were investigated using cinqPCR and IF based methods of detection.
[0451] Mitosis of hepatitis B virus-infected cells in vitro results in uninfected daughter cells (Tu et al., 2022)
[0452] It was established that in vitro, HBV cccDNA follows a pattern of linear loss up to 3 net doublings, equivalent to a final dilution of 1:8. This indicates that the vast majority of cccDNA can be cleared via inducing cell mitosis. A further serial dilution was performed to investigate whether this pattern of loss was consistent at higher levels of dilution.
[0453] Characterisation of reservoir cells: Analysis of reservoir cell phenotype
[0454] HepG2-NTCP cells infected with HBV WT at 1:32 dilution as previously described were analysed for phenotypic changes known to be hallmarks of a senescent phenotype. Cells seeded onto 24 well plates were infected with HBV WT, and serially diluted at a 1 :2 ratio until net dilution of 1 :32.
[0455] Immunofluorescent images were taken as described and stained for nuclei and HBcAg. HBcAg positive cells were analysed for nuclear circularity and size, however no significant difference to matched control cells were found.RNAseq for transcriptome analysis
[0456] These cells were further classified by transcriptomic analysis. HepG2-NTCP cells infected were infected with an RFP reporter virus and serially diluted to a 1 :64 split. RFP positive cells at this dilution were sorted via FACS and -2000 cells per sample were analysed using illumina based RNAseq. Differential gene expression (DGE) in these samples was analysed via two methods: Quasi -likelihood F-tests (QLF) and likelihood ratio tests (LRT). QLF is a more conservative method, being able to better control for type I errors but also lowering sensitivity in the process. This process is also better suited for samples with higher expected biological noise. LRT is the more sensitive statistical test to use but increases the likelihood of detecting false positives. DGEs were defined as RNA levels which were detected to be significantly different between RFP positive cell and RFP negative cells at the same dilution. Any DGEs which were also expressed in a comparison of unsplit RFP positive cells vs negative cells were removed, as these genes would be considered more as a general marker of HBV infection rather than specifically altered in HBV reservoir cells. QLF accordingly resulted in 8 DGEs including HBV RFP, while LRT resulted in generation of 110 DGEs (Supplementary data).
[0457] A number of pathways of interest were upregulated specifically related to cell arrest - specifically regarding the regulation of peptidase activity and triglyceride metabolism. To determine if DGEs were suited as markers for reservoir cells, positively regulated genes were filtered and hits which were universally expressed were eliminated. SPPl / Osteopontin was identified as a potential marker for HBV reservoir cells.
[0458] Targeting reservoir cells
[0459] A panel of senolytic drugs targeting a number of pathways of cell cycle arrest in cells which retain HBV was tested, in order to discover potential therapeutics for elimination of these target cells. A CCK8 assay for CC50 was used to determine the maximum dose without causing cytotoxicity. This was determined via CCK8 cell viability assay on cells treated with a serial dilution of each drug, and then used to calculate the CC50 for each drug in HepG2-NTCP cells (Table 6).
[0460] Table 6: CC50 for each drug in IIepG2-\ 1TCP
[0461] Compound CC50 (uM) EC50 (uM) Concentration used (uM) BPTES >50 <0.0064 1
[0462]
[0463] Teleglanastat >50 <0.0064 1ABT-737 1.5 <0.0064 0.1 Navitoclax 13.7 >0.016, <0.8 1
[0464] WEHI-539 >50 - 1
[0465] A-l 155463 >50 - 1
[0466] A-l 155463 >50 - 2 dihydrochloride
[0467] Alvespimycin 0.5 >4, <20 0.1
[0468] Dasatinib + >50 >4, <20 1
[0469] Quercetin
[0470] Gambogic Acid 0.65 <0.0064 0.1
[0471] Sabutoclax 10 <0.0064 1
[0472] A-1331852 16.8 <0.0064 1
[0473] Gossypol 15.9 <0.0064 1
[0474] Venetoclax >50 <0.0064 1
[0475]
[0476] Oblatoclax 3.9 <0.0064 0.1
[0477] / ^galactosidase assay for EC50
[0478] To determine if these compounds were effective in eliminating senescent cells, an assay was conducted to determine each drug’s EC50. HepG2-NTCP cells were treated with a lOGy dose of x-ray to induce senescence and treated with a serial dilution of each drug. A P-galactosidase assay was used to detect senescent cells, images were taken on a plate microscope and analysed using Ilastik to determine nuclei count and P-galactosidase positivity. As Datasinib is used together with Quercetin, these were measured together at a ratio of 1:10 of Dasatinib: Quercetin. Listed concentration is of Quercetin.
[0479] lOGy treatment induced P-galactosidase activity in 4.73% of untreated control cells, compared to P-galactosidase activity of 0.1% in unirradiated control cells.
[0480] Interestingly, most drugs were effective at the lowest dose tested, resulting in minimal detection of P-galactosidase positive cells compared to irradiated controls. In these cases, the EC50 was not found and instead, the lowest dose given is reported.
[0481] Using both the CC50 and EC50 two concentrations were used based on compound toxicity, listed in table 5.1. Dosage was based on a concentration which was not toxic to cells (<CC50) while having efficacy on reducing b-galactosidase activity (>EC50). In cases where this was not possible such as Alvespimycin (which has a detected EC50 higher than the CC50 meaning that it will kill cells before having an effect on P-galactosidase activity), the concentration used was as close as possible to the CC50. CC50 (higher than detectable range) and EC50 (lower than detectable range) were not detectable in other compounds, such as BPTES, in these cases, a standard concentration of luM was used.
[0482] 1:2 split cinqPCR
[0483] Efficacy in eliminating HBV reservoirs was tested in an in vitro HBV infection model. HepG2-NTCP cells infected with WT HBV were serially split at a 1:2 ratio, with cells treated with senolytics in two groups - 1 day before serial splitting began, or 1 day before splitting to a 1:16 ratio. cccDNA was then quantified at each splitting using high precision cinqPCR.
[0484] Senolytic therapy had minimal effect when delivered to unsplit infected cells (Figure 5.3), however some compounds showed efficacy. Alvespimycin treatment was found to result in adherence to the expected loss model up to p4, beyond which levels plateaued. Gambogic acid was also seen initially to result in decreased retention of cccDNA, however this result was found to be non-significant.
[0485] In contrast, senolytic treatment after theoretical generation of a plateau in cccDNA levels was found to result in a more effective treatment. Treatment with Navitoclax or A-1331852 or WEHI-539, or A-l 155463 or A-l 155463 dihydrochloride was found to result in significantly reduced HBV levels immediately after treatment at plateau.
[0486] 1:2 split using nanoluc
[0487] This experiment was replicated in separate model of HBV-nanoluc infected HepG2-NTCP cells. Previously, the focus was on treatment after the reservoir formation at a 1:16 ratio. Cells were split as the previous experiment, and at each timepoint supernatant was collected for later analysis using Nano-Gio Luciferase Assay. Cells were treated with senolytics 1 day before splitting to a 1:16 ratio. Analysis was achieved via luminometer. As seen in Figure 5, this resulted in a reduction in detected nanoluc activity in both Navitoclax and A-1331852 compared to DMSO control.
[0488] Determining the drug interaction of Navitoclax and Al 331852
[0489] The effect of a combination therapy was then determined. In pharmacology, drug interactions may be classified as additive, synergistic or antagonistic. An additive interaction results in an effect that is equal to the sum of the two drugs, while a synergistic interaction results in an effect which is greater than the sum of the two parts. Opposingly,the drugs may also result in an antagonistic interaction which results in an inhibited effect compared to a single drug.
[0490] To determine the drug interactions of Navitoclax and A-1331852 on in vitro HepG2-NTCP cells, a drug matrix assay was performed. HepG2-NTCP cells were infected with HBV-nanoluc and serially diluted as previously detailed to a final dilution of 1 : 16, and then reseeded into a 96 well format. A matrix of drug dilutions of Navitoclax and A1331852 was added and supernatant taken for analysis. In addition, a CCK8 assay on the same cells was performed to determine effect on CC50 as well. Results indicate that while higher drug concentrations appear to result in an additive effect on cell toxicity, effect on EC50 regarding elimination of HBV reservoir cells was not as clear. There were large variations between individual cells, maybe due to the low number of reservoir cells (estimated to be ~l / 500th of unsplit) causing high variance in the number of nanoluc-producing cells per well.
[0491] Discussion: Partial loss
[0492] The study comparing cccDNA levels under mitosis to mathematical modelling found that cccDNA was lost up to approximately a 1 :8 dilution from original levels when split at a 1:2 ratio, following on which cccDNA levels began to plateau, indicating a partial loss. This is consistent with many other models.
[0493] It is known through earlier studies in acute chimpanzee models and human patient data that cellular mitosis is a key factor in clearance of HBV infection. However, in chronic infection cell division is insufficient by itself to induce complete loss of cccDNA. In vitro woodchuck HBV models, and in vivo duck HBV studies have both shown cccDNA survival in daughter cells during mitosis under NA therapy.
[0494] Humanised mouse studies have shown evidence towards partial loss as well, in both woolly monkey HBV and HBV proper. In the former, cccDNA was still detected 80 days after transplantation of infected hepatocytes, while in the latter cccDNA was undetectable while under NA therapy but returned following cessation. Live cell imaging data has indicated that cccDNA post-mitotic survival is at least partially dependant on intracellular levels of cccDNA. Lower copy numbers (1-5 copies / cell) were associated with almost complete loss during mitosis, while higher levels (6-20 copies / cell) were more likely to result in survival (17-20% retention). Finally, several studies in chronic HBV patients with long term NA use have detected persistence of cccDNA even after years of ongoing mitosis under prevention of viral replication.
[0495] Overall, this partial loss model is well documented in the literature, and has been speculated to occur due to retention of cccDNA positive cells via mitotic arrest.Discussion: Reservoir cells
[0496] The current study has identified the existence of mitotically resistant HBV reservoir hepatocytes in a cell culture model and an in vivo mouse model. An important distinction needs to be made as to whether these cells are quiescent or senescent, i.e., whether this mitotically inactive state is temporary or permanent.
[0497] Discussion: Senescence
[0498] Reservoir cells express upregulated P-galactosidase and p53 which are markers of senescence. Moreover, RNAseq data has indicated these cells have upregulated expression of Osteopontin, a cytokine and major component of the SASP. Contrastingly however these cells also do not express the traditional phenotypic presentation of senescent cells - i.e. an enlarged and flattened appearance with irregularly shaped nuclei. It is however known that senescence can be initiated via several pathways, which may not manifest in the same expression of biomarkers or phenotype. Indeed, it is established that there is no one single marker which is sufficient for identification of a cell as senescent, hence why a combination of markers is used for increased specificity. In general, pathways for senescence initiation are grouped into three categories: replicative, damage or oncogene associated.
[0499] Discussion: Quiescence
[0500] Unlike senescence, which is considered a permanent cell arrest, quiescent cells are able to re-enter the cell cycle. The two terms however are inextricably linked, and in many cases are difficult to distinguish from one another due to many overlapping biomarkers.
[0501] P-galactosidase, the gold standard for detection of senescent cells, is also known to be expressed in quiescent cells under serum starvation or high confluency. Moreover while it is known to be a marker of senescence, P-galactosidase is not actually needed for initiation or maintenance of a senescent phenotype, and may reflect more accurately an associated increase in lysosomal activity. Paradoxically, p53 has also been found to both be an inducer of cellular senescence via activation of p21, as well as an inhibitor via its inhibition of the mTOR pathway. p53 mediated quiescence has also been found to occur via mTOR inhibition, as well as upregulation of p53 targets Gif-1 and Necdin. A number of other biomarkers of senescence also known to be important for quiescence include p21, and Rb. It can therefore be argued that these are markers of general cell cycle arrest rather than specifically senescence or quiescence.It has been reported that quiescence is not simply a binary aspect of the cell, and functions more akin to a heterogenous state with varying degrees of depth. Shallower quiescence are more readily available to return to the cell cycle, while deepening quiescence represents a path towards permanent senescence. Interestingly, the quiescence depth was found to alter the transcriptome of the cell, particularly in relation to lysosomal gene expression. Deeper quiescence was found to result in higher lysosomal gene expression, but lower lysosomal function. This results in an increased lysosomal mass, and with deeper quiescence associated more closely to a final senescent phenotype, there is a potential causal link between this increased lysosomal mass and common biomarkers of senescence associated with the lysosome such as P-galactosidase and lipofuscin.
[0502] This dynamic modulation of the transcriptome may alter the interpretation of our RNAseq results if HBV reservoir cells are quiescent, as the results only captured one level of the quiescent transcriptome.
[0503] Example 6: In vivo elimination of HBV cccDNA reservoir cells
[0504] To translate in vitro senolytics findings into an in vivo animal model and validate the results, a mouse model of HBV infection was established. Using this model, the efficacy of Navitoclax and A-1331852 in elimination of senescent cell subsets harbouring cccDNA was investigated. An AAV was used to establish an episomal DNA construct expressing GFP in the liver of mice as a model for HBV, as the AAV DNA genome is similarly known to be lost during mitosis.
[0505] An Adeno Associated Virus (AAV) vector was used as a model for HBV, as this vector has been previously found to result in >99% GFP expression in murine liver. This may be delivered either via simple intraperitoneal (IP). To optimise the amount of GFP DNA delivered so that it would mimic the levels of cccDNA in a HBV infected liver, the DNA at 2 different concentrations.
[0506] Both BALBc and C3H / HeN mice were injected with AAV8 encoding, at 2 different concentrations - 3xlO10and 5xlO10vg / mouse, using an IP injection. These concentrations were calculated to result in approximately 30% and 50% expression of GFP respectively, assuming a linear relationship between dose and expression. Another group of C3H mice were also injected with the previous GFP plasmid in order to determine efficacy in the new strain. Mice were then treated with twice weekly CC14 injections as previously described, and harvested at 2, 4 and 6 weeks post GFP delivery. Livers were taken for GFP analysis and H&E histology. Delivery of GFP plasmid did not generate a strong GFP signal in the vehicle control at 2 weeks, and was undetectableentirely in the CCU treated mice, resulting in failure to generate detectable reservoir cells. AAV8 treatment was therefore used for following experiments.
[0507] After two weeks, GFP expression was detectable, with intensity increasing to a stable level at 4 weeks, and is seen to be at a similar level at 6 weeks in both BALBc and C3H mouse strains. Under treatment with CCh, BALBc mice showed increased expression of GFP in a dose dependent manner, however the same is not seen in the C3H condition, with similar levels of GFP between the different concentrations. Under CCU treatment in both mouse strains there are high GFP expressing hepatocytes, as characterised by their large round nuclei and cell size. However, in the C3H mice, there are no high GFP expressing Kupffer cells. This is useful for image analysis in preventing false positives. C3H mice were used for the following experiments. As there was not a detectable difference in GFP expression between AAV8 concentrations, the higher dose was chosen for further experiments for consistency.
[0508] H&E staining of BALBc mice indicated that at 2 weeks, there was a large amount of cell death and liver turnover due to CCU treatment. This stabilised at 4 weeks, and mice at 6 weeks demonstrate no significant difference to control mice. In contrast, C3H mice do not show as high levels of cell death at 2 weeks, however this response is sustained at 4 and 6 weeks, as indicated by the white unstained areas within cells at 4 and 6 weeks, suggestive of chronic inflammation. Moreover, at 6 weeks the appearance of brown foci near central veins was observed, which was suspected to be lipofuscin, a marker of cellular aging.
[0509] Characterisation of reservoir cells in mouse model
[0510] After validating that GFP positive cells are retained following liver mitosis in C3H mice, the cells were characterised via staining of biomarkers. To demonstrate that these cells expressed senescent markers, these liver sections were stained for p53. As lipofuscin is known to be autofluorescent, an additional staining with anti-GFP was performed, which was then conjugated to a secondary which is fluorescent at 546nm. Liver turnover results in retention of some GFP+ cells, which are positive for p53. These GFP+ cells were mainly localised around central veins. Staining for b-galactosidase activity which is another biomarker of cellular senescence, demonstrated that it accumulates around central veins in CCI4 treatment. GFP+ cells are therefore positive for p53 and localise in the same hepatic localisation as b-galactosidase. These GFP+ cells are in mitotic arrest and retain GFP due to their inability to divide.
[0511] Elimination of reservoir cells in mouse modelNavitoclax and A-1331852 were identified as potential therapeutics for treatment of HBV reservoir cells in the in vitro experiments, verified in the mouse model. A similar experimental plan to previous in vivo experiments was followed, injecting C3H / HeN mice with GFP AAV8, and twice weekly injections of CC14 for 6 weeks (Figure 6.x. a). Following this, mice were treated with 1.5mg / kg ofNavitoclax, A-1331852 or both daily for a total of 14 days. Mice were then harvested, and histology compared.
[0512] Mouse weight was monitored throughout the treatment as an indicator of health and assessment of potential toxicity of the compounds. Significant weight loss, defined arbitrarily as a decrease in more than 20% from baseline, would indicate a toxic effect of drug treatment. Mouse weight was not found significantly decrease over the duration, and in most treatment groups increased, indicating that the treatment was well tolerated.
[0513] To evaluate the efficacy of both Navitoclax and A-1331852 in reducing GFP positive cells, OCT embedded liver samples were sectioned at 8pm and mounted on glass slides, fixed with 4% PF A and stained with anti-GFP and p53. Images were analysed using a combination of Ilastik and manual counting for detection of anti-GFP positive cells, and normalising this to the number of nuclei in at least 3x 1000x1000pm fields of view per mouse. Navitoclax monotherapy resulted in reduction of GFP+ cells compared to untreated CCU mice, however A1331852 did not reduce levels of GFP+ cells. Combination therapy resulted in a similar reduction in GFP+ cells as Navitoclax monotherapy, suggesting that Navitoclax is effective but not A1331852.
[0514] Discussion
[0515] Different mouse strains are known to have different properties in relation to susceptibility to persistence of HBV antigens. C3H / HeN mice have been found to retain HBsAg levels for a long time, retaining positivity for at least 8 weeks post infection.
[0516] It is known that in mice transgene expression is associated with liver zonation, resulting in highest level of transduction in hepatocytes closer to the central veins, and consequently decreasing efficiency moving from mid-lobe to periportal regions. Interestingly, this phenotypic zonation is reversed in cynomolgus and rhesus macaque models with higher expression around portal areas and decreasing towards the central veins, while both newborn mice (<24h) and 1 week old macaques developed a randomly distributed phenotype. In the 6-week model, the central vein dominated expression. This transgene expression derived localisation therefore prevents commentary on hepatocyte localisation as a factor in development of senescence in hepatocytes.
[0517] Carbon tetrachloride (CCh) is a well-known and common laboratory reagent used to induce hepatotoxicity via its metabolism by hepatocytes, resulting in its conversioninto a number of reactive oxygen species, which result in lipid peroxidation and oxidation of liver proteins and DNA. It is liver tropic and results in consistent liver damage in a dose-dependent fashion, making it a reliable method of inducing liver injury.
[0518] Other methods of inducing liver damage include a partial hepatectomy, where >60% of a liver is surgically removed, inducing regeneration and mitosis of the remaining liver. This approach is invasive and requires surgical skill, but is not associated with chemical toxicity, and results in a comparatively lower inflammatory response. This may not model HBV induced liver damage and mitosis as closely due to this, as HBV flares are known to induce a high inflammatory response.
[0519] Another method that may induce liver damage is putting mice on a high fat diet to induce steatosis and inflammation. This is a slower method of inducing liver damage however and is more fitting for studying progression of metabolic dysfunction-associated fatty liver disease than in modelling HBV induced liver turnover. It does however model chronic inflammation, which may be an important factor in generation of senescent cells.
[0520] Cells retaining GFP post-mitotic induction were also positive for p53 and associated with b-galactosidase. Although it is known that there is no universal biomarker for cellular senescence, these are two of the most well known and studied. In addition, b-galactosidase is difficult to detect due to the assay requiring its enzymatic activity, which is present in fresh tissue for several hours, but degrades over time and is likely lost upon fixation or long-term cryopreservation.
[0521] Previous studies have found that CCh treated mice result in lipofuscin related autofluorescence], necessitating the use of an anti-GFP antibody to validate GFP expression. GFP+ cells were locally associated with lipofuscin granules, which appear as brown pigment. These are aggregates of cross-linked proteins and lipid byproducts of failed catabolism, which cannot be degraded by the proteasome or excreted via exocytosis. Mitotically active cells are able to dilute their accumulated lipofuscin via mitosis, however this cannot happen with cells in cell cycle arrest such as senescent cells resulting in its buildup. Its presence however is not specific to only senescent cells, as aged cells with slower mitotic cycles and cells in temporary quiescence may also build up lipofuscin. Other post-mitotic cells such as neurons may also build up stores of lipofuscin, rendering it an indication but not confirmation of senescence.
[0522] Efficacy of Navitoclax is demonstrated in vivo in elimination of the modelled reservoir cells, shown via reduction of GFP+ cells. WEHI-539, A-l 155463 or A-11554632HC1 have similar inhibition profiles to Navitoclax. Although in vitro testing indicated A1331852 may also reduce reservoir cells, this was not shown in the model. As Navitoclax is a broad BCL family inhibitor while A1331852 is more selective forBCL-XL, it may be that the broad inhibition of BCL family proteins was required for effective elimination in the model, whereas only inhibiting BCL-XL was insufficient. Moreover, as their combined therapy resulted in a similar level of GFP+ cell reduction as Navitoclax monotherapy, the combination did not have any measurable synergistic or additive effect.
[0523] Dosage was informed by in vitro testing data including CC50 and IC50 data for HepG2-NTCP cells in Chapter 5, however this may not be entirely accurate in the in vivo model. Due to the novel nature of these compounds, particularly A1331852, there is minimal data in the literature on effective dosages, and so A1331852 may have been underdosed, resulting in no measurable effect.
[0524] Conclusion
[0525] A mouse model of HBV reservoir cell formation was established, and demonstrated these cells are known to express biomarkers associated with cell arrest and senescence including b-galactosidase, lipofuscin and p53. This model demonstrates HBV survival via maintenance in post-mitotic hepatocytes. These cells therefore are a target for therapeutics, and treatment with Navitoclax has demonstrated efficacy in elimination of this cellular population, however A-1331852 did not at the dosage tested. Dose optimisation tests are recommended, given the in vitro results demonstrated A-1331852 was effective.
[0526] Example 7: Elimination of cccDNA reservoir cells by DT2216 in vitro
[0527] The majority of cccDNA is lost with mitosis, however, a rare cell population maintains cccDNA. The persistently infected cells displayed at least 2 markers for senescence: p21 expression and intrinsic P-galactosidase activity (Figure 2B). Moreover, when the reservoir cell transcriptome was analysed using low-input RNAseq, it was found that persistently infected cells upregulate senescence-associated pathways, including peptidase activity and triglyceride metabolism. To test the hypothesis that senescent infected cells act as reservoirs to maintain viral infection by not undergoing mitosis and evading the antiviral immune response, the following example specifically targeting this population of reservoir cells to cure HBV.
[0528] Cells were treated and passaged as described previously and according to the experimental timeline is shown in Figure 7. Figure 7 shows a three trial with different doses of DT2216. This experiment confirms that reservoir cells can be eliminated in vitro by DT2216, a small molecule drug that eliminates senescent cells (currently in Phase I clinical trials as an anti-cancer agent and provided in-kind owned by DialecticTherapeutics, USA; CSO CI Tremaine and co-founder Al Zhou). After 4 days of treatment, 0.5pM of DT2216 induced a ~20-fold reduction in reservoir cells compared to DMSO controls (Figure 7). No significant toxicity was observed in non-infected cells at these doses by cell morphology or viability (Figure 7B), suggesting a specific mechanism of clearance. Thus, DT2216 represents a completely novel approach to treat and / or cure hepatitis B infection.
[0529] Based on a first principles approach, it is expected that DT2216 would be given to patients on long-term nucleoside analogue therapy (current standard of care) and possibly along with interferon-alpha to stimulate the immune response, similar to the approaches taken with other investigational drugs to treat Hepadnavirus infection.
[0530] It is understood that the foregoing examples are merely illustrative of the present invention. Certain modifications of the articles and / or methods employed may be made and still achieve the objectives of the invention. Such modifications are contemplated as within the scope of the claimed invention.REFERENCES
[0531] Evangel ou et al., (2017) Methods Mol Biol. 1534: p. 111-119. Tachtatzis et al., (2015) PLoS One, 2015. 10(5): p. e0127511. Tu et al., (2020) Antiviral Res. 181: p. 104865.
[0532] Wettengel et al. (2021) Viruses 13(8).
[0533] Wing et al. (2019) Life Sci. Alliance 2(2) e201900355.
Claims
CLAIMS:
1. A method of treating a Hepadnavirus infection in a subject suffering therefrom, comprising administering to the subject a selective inhibitor of one or more senescence-associated BCL-2 family proteins.
2. Use of a selective inhibitor of one or more senescence-associated BCL-2 family proteins in the preparation of a medicament for treatment of Hepadnavirus infection in a subject suffering therefrom.
3. A pharmaceutical composition for treating Hepadnavirus infection in a subject suffering therefrom, said pharmaceutical composition comprising a selective inhibitor of one or more senescence-associated BCL-2 family proteins.
4. The method of claim 1 or the use of claim 2 or the pharmaceutical composition for use of claim 3, wherein the Hepadnavirus is Hepatitis B virus (HBV).
5. The method, use or pharmaceutical composition for use of claim 4, wherein the subject is suffering from chronic HBV infection.
6. A method of preventing chronic Hepadnavirus infection in a subject suffering from acute Hepadnavirus infection, comprising administering to the subject a selective inhibitor of one or more senescence-associated BCL-2 family proteins.
7. Use of a selective inhibitor of one or more senescence-associated BCL-2 family proteins in the preparation of a medicament for preventing chronic Hepatitis B virus (HBV) infection in a subject suffering from acute HBV infection.
8. A pharmaceutical composition comprising a selective inhibitor of one or more senescence-associated BCL-2 family proteins for preventing chronic Hepatitis B virus (HBV) infection in a subject suffering from acute HBV infection.
9. The method of any one of claims 1 or 4 to 6, or the use of any one of claims 2, 4, 5 or 7, or the pharmaceutical composition for use according to any one of claims 3 to 5 or 8, wherein the one or more senescence-associated BCL-2 family proteins are selected from the group consisting of BCL-2, BCL-XL, BCL-W, MCL-1, BFL-1 / A1, and BCL2L10 or their relevant orthologues, or senescence-associated isoforms of any one thereof.
10. The method, use or pharmaceutical composition for use of claim 9, wherein the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is a selective inhibitor of BCL-2 / BCL-xL, a selective inhibitor of BCL-2 / BCL-xL / BCL-w, or a selective inhibitor of BCL-xL.
11. The method of any one of claims 1, 4 to 6, 9 or 10, or the use of any one of claims 2, 4, 5, 7, 9 or 10, or the pharmaceutical composition for use according to any one of claims 3 to 5 or 8 to 10 , wherein the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is selected from a small molecule inhibitor, an oligonucleotide inhibitor, a polynucleotide inhibitor, a peptide inhibitor and a protein inhibitor.
12. The method of any one of claims 1, 4 to 6 or 9 to 11, or the use of any one of claims 2, 4, 5, 7 or 9 to 11, or the pharmaceutical composition for use according to any one of claims 3 to 5 or 8 to 11, wherein the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is selected from the group consisting of Navitoclax (ABT-263), A-1551852, A-1331852, A-1155463, A-1155463 dihydrochloride, A-1210477, Venetoclax (ABT-199), ABT-737, Sonrotoclax (BGB- 11417), S63845, S64315 (MIK665), S55746 (BCL201), AZD5991, AZD4320, BT- 1197, AMG-176, WEHI-539, IS21, Obatoclax Mesylate (GX15-070), Subatoclax (BI-97C1), Maritoclax (Marinopyrrole A), TW-37, UML77, BDA-366, BM-1252, BXI-61, BXL72, HA14-1, BDA366, APG-2575 (lisaftoclax), BH3I-1, DT2216, VU661013, a perylene quinone mycotoxin (e.g., Altertoxin I, Altertoxin II, and alterperylenol from Alternaria alternata) and derivatives thereof, gossypol and enantiomers thereof, AT- 101, siRNA, Oblimersen, and tetrocarcin A secreted by Micromonospora sp.
13. The method, use or pharmaceutical composition for use of claim 12, wherein the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is a small molecule BH3 mimetic drug.
14. The method, use or pharmaceutical composition for use of claim 13, wherein the small molecule BH3 mimetic drug is Navitoclax (ABT-263).
15. The method, use or pharmaceutical composition for use of claim 13, wherein the small molecule BH3 mimetic drug is Venetoclax (ABT-199).
16. The method, use or pharmaceutical composition for use of claim 12, wherein the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is asmall molecule selected from the group consisting of Navitoclax, Venetoclax, A-1155463, A-l 155463 dihydrochloride, WEHI-539, A-1551852, DT2216 and any combinations thereof.
17. The method, use or pharmaceutical composition for use of claim 16, wherein the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is A-1551852.
18. The method, use or pharmaceutical composition for use of claim 16, wherein the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is A-l 155463.
19. The method, use or pharmaceutical composition for use of claim 16, wherein the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is A-l 155463 dihydrochloride.
20. The method, use or pharmaceutical composition for use of claim 16, wherein the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is WEHI-539.
21. The method, use or pharmaceutical composition for use of claim 16, wherein the selective inhibitor of the one or more senescence-associated BCL-2 family proteins is DT2216.
22. The method, use or pharmaceutical composition for use of claim 11, wherein the oligonucleotide inhibitor and / or polynucleotide inhibitor is an RNA interference (RNAi) molecule.
23. The method, use or pharmaceutical composition for use of claim 22, wherein the RNAi molecule, which is a selective inhibitor of the one or more senescence-associated BCL-2 family proteins, is Oblimersen (G3139).
24. The method of any one of claims 1, 4 to 6 or 9 to 23, or the use of any one of claims 2, 4, 5, 7 or 9 to 23, or the pharmaceutical composition for use according to any one of claims 3 to 5 or 8 to 23, wherein administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject decreases the number of HBV cccDNA molecules in the subject.
25. The method, use or pharmaceutical composition for use of claim 24, wherein administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject decreases the number of HBV cccDNA molecules in the subject by at least 2-fold relative to the level of HBV cccDNA in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
26. The method, use or pharmaceutical composition for use of claim 24, wherein administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject decreases the number of HBV cccDNA molecules in the subject by at least 3 -fold relative to the level of HBV cccDNA in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
27. The method, use or pharmaceutical composition for use of claim 24, wherein administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject decreases the number of HBV cccDNA molecules in the subject by at least 4-fold relative to the level of HBV cccDNA in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
28. The method of any one of claims 1, 4 to 6 or 9 to 27, or the use of any one of claims 2, 4, 5, 7 or 9 to 27, or the pharmaceutical composition for use according to any one of claims 3 to 5 or 8 to 27, wherein administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject reduces the number of senescent cells infected by HBV in the subject relative to the number of senescent cells infected by HBV in the subject prior to administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins.
29. The method, use or pharmaceutical composition for use of claim 28, wherein administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject reduces the number of senescent cells infected by HBV in the subject by more than 50%.
30. The method, use or pharmaceutical composition for use of claim 28, wherein administration of the selective inhibitor of one or more senescence-associated BCL-2 family proteins to the subject results in clearance of senescent cells infected by HBV in the subject.
31. The method of any one of claims 1, 4 to 6 or 9 to 30, wherein the selective inhibitor of one or more senescence-associated BCL-2 family proteins is administered orally to the subject.
32. The use of any one of claims 2, 4, 5, 7 or 9 to 30, wherein the medicament is an oral formulation.
33. The pharmaceutical composition for use according to any one of claims 3 to 5 or 8 to 30, wherein the pharmaceutical composition is an oral formulation.
34. The method of any one of claims 1, 4 to 6 or 9 to 31, or the use of any one of claims 2, 4, 5, 7 or 9 to 29 or 32, or the pharmaceutical composition for use according to any one of claims 3 to 5 or 8 to 29 or 33, wherein the subject is receiving one or more additional treatments or treatment regimens for HBV infection.
35. The method, use or pharmaceutical composition for use of claim 34, wherein the additional treatment comprises antiviral therapy and / or interferon.
36. The method, use or pharmaceutical composition for use of claim 35, wherein the antiviral therapy comprises a nucleoside analogue.
37. The method, use or pharmaceutical composition for use of any one of claims 34 to 35, wherein the antiviral therapy comprises one or more of entecavir (Baraclude), tenofovir disaproxil fulmarate (Viread), tenofovir alafenamide (Vemlidy), lamivudine (Epivir) and adefovir (Hepsera).
38. A method of monitoring progression of Hepadnavirus infection in a subject currently or previously infected with Hepadnavirus, the method comprising:i) determining a level of senescent Hepadnavirus infected cells in a sample obtained from the subject based on the presence and / or level of one or more markers of cell senescence in the sample;ii) comparing the level of senescent Hepadnavirus infected cells in the sample determined at i) to a reference level for senescent Hepadnavirus infected cells; and iii) making a determination on progression of the Hepadnavirus infection in the subject based on ii),wherein a level of senescent Hepadnavirus infected cells in the sample which is higher than the reference level is indicative of worsening Hepadnavirus infection and / or chronic hepadnavirus infection in the subject,wherein a level of senescent Hepadnavirus infected cells in the sample which is lower than or equal to the reference level is indicative of regression or improvement in the Hepadnavirus infection in the subject.
39. The method of claim 38, wherein the Hepadnavirus is HBV.
40. The method of claim 38 or 39, wherein the sample is taken from a subject suffering from, or previously diagnosed with, chronic infection.
41. The method of any one of claims 38 to 40, wherein a worsening Hepadnavirus infection and / or chronic Hepadnavirus infection is indicative that the subject is not responding to treatment for the infection, and a regression or improvement in the Hepadnavirus infection is indicative that the subject is responding to treatment for the infection.
42. The method of any one of claims 1, 4 to 6 or 9 to 41, or the use of any one of claims 2, 4, 5, 7 or 9 to 29 or 37, or the pharmaceutical composition for use according to any one of claims 3 to 5 or 8 to 29 or 37, wherein the subject is a mammal.
43. The method of claim 42, wherein the mammal is a human, a non-human primate, a cat, a dog, or a horse.
